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1. Introduction 
1.1. Biogenesis and function of miRNAs 
More than 25 years ago, first observations of the small RNA lin-4 were made in 
C. elegans. Much to the surprise of the researchers around Lee RC in the Ambros 
group, the RNA was not coding for any protein. Furthermore, the authors even found 
that lin-4 performed transcriptional regulation on another gene, lin-14 by suppressing 
its expression via complementary antisense RNA interaction1. While those findings 
were received with high interest in the early 1990’s, the magnitude and importance for 
today’s biology were not clear at that time. It was not until the early 2000’s that those 
small, non-coding RNAs were regarded as their own class of regulatory RNAs and due 
to their size of around 22 nucleotides were termed microRNAs (miRNAs)2. Today, it is 
generally understood that miRNAs are involved in multiple cellular processes in plants 
as well as animals 3,4.  
  
Figure 1 – Biogenesis and function of miRNAs 
a) Adapted from Lodish et al. and Gebert et al. 4,5, miRNAs undergo extensive processing, shortening 
the length of the primary transcript from step to step. b) Adapted from Peter et al.6, the complex multi-
layered network of miRNA based translational regulation 
 
In short, the biogenesis of miRNAs is based on the nuclear transcription of miRNA 
genes by RNA polymerase II, resulting in the primary transcripts, pri-miRNAs. This 
RNA segments are often polycistronic units and can contain multiple miRNA hairpin 
structures. A protein complex, consisting of the RNAse III endonuclease Drosha, as 
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well as the microprocessor complex subunit DGCR8, is able to recognize the hairpin-
motifs and generates 60-70 nt stem-loop structures, the pre-miRNA.  
After those stem-loops are transported to the cytosol, facilitated by Ran-GTP and 
Exportin, further processing is applied: The protein complex, consisting of Dicer, a 
RNAse III endonuclease, and the RNA-binding co-factor TRBP, cleaves the pre-
miRNA. The resulting RNA of 22 nt length is the mature miRNA, a duplex consisting of 
the miRNA and its complementary strand, often referred to as miRNA* (“star-strand”). 
The miRNA*, or sometimes also called “passenger strand”, undergoes RNA 
degradation, as the thermodynamically favored single stranded miRNA is loaded into 
the RISC (Figure 1a) 4,5. 
With the Argonaut proteins (Ago), the miRNA-RISC recognizes target mRNAs based 
on sequence complementarity of the “seed region”, located in the 3’ UTR of the mRNA. 
Thus, miRNA regulation of protein expression is based on anti-sense matching of only 
about eight bases, nucleotides two to seven of the miRNA’s 5’ end, to the mRNA seed 
region. While a perfect match of bases is common in plants3, it is highly uncommon in 
animals. The partial matching of only about seven or even six bases can cause 
translational repression, following different thermodynamic rules of anti-sense binding, 
like e.g. “Wobble hypothesis” 7. 
Altogether, miRNAs have added a new level of complexity to translational regulation 
of protein expression: While one miRNA can target multiple mRNAs, one single mRNA 
can also be the target of many different miRNAs 6 (Figure 1b). 
Since the first studies of Lee et al., more than 80,000 publications with the search term 
“miRNA” were registered in NCBIs database Pubmed.gov 
(https://www.ncbi.nlm.nih.gov) until early 2019, showing the vast increase of interest 
and therefore knowledge in this field. 
 
1.2. miRNAs in breast cancer 
Breast cancer is one of the leading causes of cancer deaths worldwide 8. According to 
the American cancer association, in 2018 more than 260,000 women were estimated 
to be newly diagnosed with breast cancer, and almost 41,000 deaths will have  
occurred 9. MiRNAs play a major role in the development and persistence of breast 
cancer 10,11. While breast cancers are a group of highly heterogeneous tumors, often 
classified by their status of hormone receptors 12,13, miRNAs seem to play an 
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ubiquitous role, either as tumor suppressor or promotor, so called oncomiRs 14. While 
tumor suppressing miRNAs are often shown to inhibit processes like epithelial to 
mesenchymal transition, uncontrolled proliferation or de-toxifying processes, 
oncomiRs are regarded as the contrary and often amplify proliferation, metastasis and 
enable avoidance of apoptosis 15. 
The following chapters of this thesis will focus on two prominent miRNAs, miRNA-27a 
(miR-27a) and miRNA-200c (miR-200c) both with contrary roles on the first sight.  
MiRNA-200c and the miR-200c family, are some of the most investigated miRNAs 
today and seem to be among the most effective miRNAs suppressing tumor growth 
and metastasis. In chapter 3 the loss of miR-200c, induced by a genomic knock-out 
(KO) in epithelial breast cancer cells, was described by analysis of the proteome. Novel 
potential targets were identified, and the cellular phenotype of the KO cell line was 
characterized. In chapter 4, the focus was placed on migratory targets found in the 
previous proteome analysis and are further investigated, by utilizing novel cell line 
constructs and 1D migration assays. 
The first part of this work, however, focuses on miRNA-27a (miR-27a). While this 
miRNA is often regarded as a potent oncomiR, in our study in chapter 2 we found a 
positive correlation of high miR-27a expression and the beneficial survival in a 
subgroup of patients with luminal A breast cancer undergoing anti-estrogen therapies, 
as well as a potential molecular mechanism for this observation.  
 
1.2.1. MiRNA-27a – an oncomir with ambivalence in breast cancer 
MiR-27a is investigated in multiple indications and disease states. It has been shown 
that this miRNA can exhibit strong influence in metabolic settings 16, especially 
cholesterol homeostasis and arteriosclerosis 17, as well as in neurodegenerative 
disorders 18 and differentiation of benign cells, like myoblasts 19. Of interest, miR-27a 
was also shown to regulate endothelial differentiation in breast cancer stem-like cells 
20, and also correlate to the metastatic burden of the patients, i.e. miR-27a was 
increased in more aggressively spreading tumors 21. Based on this and similar findings 
in oncological settings, miR-27a can be regarded as a tumor promoting oncomiR, due 
to its ability to increase cancer progression and as well as resistance to 
chemotherapeutic agents 22-24.  
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In “2. MiRNA-27a Sensitizes Breast Cancer Cells To Treatment With Selective 
Estrogen Receptor Modulators” we suggest that expression of miR-27a could also be 
utilized as biomarker of functional estrogen receptor expression in luminal A breast 
cancer. Thus, identifying miR-27a a potential predictor for the response of anti-
estrogen therapies in patients, not in objection to its role as oncomiR 25.  
 
1.2.2. Tumor suppressing effects of miRNA-200c in breast cancer 
The miR-200 family consists of five members: miR-200a, miR-200b, miR-200c, 
miR-141 and miR-429. While the whole family shares common sequence elements as 
well as functions, described in more detail in chapter 3.2, the most investigated 
representative of this family is miR-200c.  
 
Figure 2 – miRNA-200c as “watchdog of cancer progression” 
Adapted from Mutlu et al. 26 
 
In general, miR-200c is regarded as an effective tumor suppressor and sometimes 
even discussed as “watchdog of cancer progression” 26, due to its many inhibiting 
effects in cancer progression. Previous work in our group, conducted by Kopp et al., 
investigated the effect of miR-200c upregulation in sensitizing breast cancer cells to 
anthracyclines. It was shown that the increased efficacy of the doxorubicin treatment 
was facilitated by the decreased expression of TRKB and BMI1 27. In another study, 
the inhibition of the oncogene KRAS by miR-200c expression, showed a direct anti-
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proliferative effect on triple negative MDA-MB-231 breast cancer cells 28. While all 
those findings were made by utilizing miRNA-precursor or mimic based 
overexpression, novel developments in gene editing opened new experimental 
perspectives. Therewith, we generated a TALENs based genomic knock-out 29,30 in the 
miR-200c high expressing MCF7 breast cancer cells. This long-term stable approach 
allowed for a broad screen of changes in the proteome, resulting in many putative, but 
previously unrelated targets, which could be influenced by miR-200c, as discussed in 
3.4. 
The generated knock-out cell line, as well as modified MDA-MB-231 cells, were utilized 
to further investigate the possible effects of miR-200c on epithelial to mesenchymal 
transition or closely related processes. Novel targets from 3.3.4 were analyzed for their 
role in migration and cellular organization, as described in more detail in chapter 4. 
1.3. Aim of the thesis 
In this thesis, the effect of two different miRNAs, miR-200c and miR-27a, in breast 
cancer was to be evaluated. Both miRNAs have known roles in disease, development 
of tissues and have previously been found to have multiple effects in cancer. 
With the focus on breast cancer, the profile of both miRNAs was to be evaluated and 
novel functions investigated. For a comprehensive approach, different stably modified 
breast cancer cell line models had to be generated, either as knock-out constructs. 
Causing depletion of the miRNA, or as inducible overexpression constructs, gaining 
full time- and dose control on the expression of miRNAs. 
With these novel perspectives on the function of both miRNAs, their potential use as 
either biomarker or even therapeutic was to be discussed. 
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2. MiRNA-27a Sensitizes Breast Cancer Cells To Treatment With 
Selective Estrogen Receptor Modulators 
 
The following sections are directly adapted from the original publication, which was 
finally published as Ljepoja et al., Breast. 2019 Feb;43:31-38.  
Sections may have been moved for consistency 
 
MiRNA-27a Sensitizes Breast Cancer Cells To Treatment With Selective 
Estrogen Receptor Modulators 
Bojan Ljepoja1, Jonathan García-Roman1, Ann-Katrin Sommer1, Ernst Wagner1, 
Andreas Roidl1*, Breast. 2019 Feb;43:31-38 
1Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-
Universität München, Munich, Germany 
 
Contributions: 
 
BL performed the experiments and wrote the manuscript. JGR performed the analysis 
of transcription factor and ERE-binding sites. AS generated the TAM6 cells. EW 
provided conceptual advice. AR conceived the study and wrote the manuscript. All 
authors commented on the manuscript and conclusions of this work. 
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2.1. Abstract 
Background: MicroRNA-27a (miR-27a) is a small non-coding RNA, shown to play a 
role in multiple cancers, including the regulation of ERα expression in breast cancer. 
Most ERα positive tumors are treated with Selective Estrogen Receptor Modulators 
(SERMs) and thus the role of miR-27a expression in response to SERM treatment is 
of interest. 
Methods: Tamoxifen resistant cells were generated by molecular evolution with six 
cycles of tamoxifen treatment. MCF7 and T47D luminal A breast cancer cell lines were 
either treated with miR-27a mimics, or ER-signaling was modulated ectopically. The 
changes were analyzed with RT-qPCR, western blot and transcriptional activity ERE-
reporter assays. Moreover, response to SERM treatments (tamoxifen, endoxifen and 
toremifen) was investigated by viability and apoptosis measurements. An in silico 
analysis of survival data from the METABRIC study was performed in order to assess 
the prognostic value of miR-27a for response to SERM treatment. 
Results: Tamoxifen-resistant cells showed decreased expression of ERα and miR-
27a. The overexpression of miR-27a increased the levels of ERα, while modulation of 
ERα decreased miR-27a expression. High miR-27a expression increased the 
sensitivity of MCF7 and T47D cells to SERM treatments and re-sensitized the cells to 
tamoxifen. Patient survival of luminal A breast cancer patients that underwent 
endocrine therapies was better in groups with high miR-27a expression. 
Conclusion: MiR-27a sensitized luminal A breast cancer cells to SERM treatments 
based on a positive feedback loop with ERα. An increased overall-survival of ER-
positive breast cancer patients that underwent endocrine treatments and displayed 
high miR-27a levels was found. 
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2.2. Introduction 
Breast cancer is one of the leading causes of cancer deaths worldwide8. The group of 
breast cancers is highly heterogeneous in its prevalence, short- as well as long-term 
mortality. Therefore, the tumors are characterized and clustered according to different 
characteristics. The most common approach is based on determination of receptor 
expression, like the estrogen- and progesterone receptor (ER and PR) or HER2. While 
luminal A breast cancer, with positive expression of ER and PR, are the most prevalent 
tumors, they are also considered least harmful, as they tend to be less aggressive and 
in general well treatable with endocrine therapies, like estrogen receptor modulators 
(SERMs)12,13. 
Nevertheless, the ATLAS trial showed that therapies with anti-endocrine agents, e.g. 
the SERM tamoxifen (TAM), should be considered for a full treatment period of at least 
5 years, ideally even 10 years and longer for best effects 31. Still, previous reports 
suggest that as much as 40% of all ER-positive breast cancers treated with adjuvant 
tamoxifen undergo relapse, with eventually fatal outcomes 32. It is unclear whether this 
poor response is based on initial (ab initio) resistance to the therapies or due to 
acquired (de novo) resistance. 
Moreover, different side effects of SERMs, like increased risk for cervical carcinoma or 
osteoporosis, becloud their positive effects. In order to attenuate long-term adverse 
effects of SERM treatments, the ESMO guidelines suggest a switch of treatment to a 
newer class of drugs, i.e. selective estrogen receptor down regulators (SERDs) like 
fulvestrant. SERDs are often considered in long term second line treatments (after 5 
years or more). Also transitions to aromatase-inhibitors like anastrozol are made 33. 
While some of these approaches may circumvent adverse effects and resistance, the 
survival of luminal A breast cancer patients is declining over time, indicating that the 
current treatment approaches for luminal A tumors cannot be considered optimal for 
all luminal A tumors, in regard of their long-term outcome 31. 
Thus, there is a practical need for further diversification of breast cancer in general and 
especially for ER-positive tumors. Additional sub-classifications of breast cancer 
tumors were suggested, e.g. the screening for GATA3 mutations 34-36. While multiple 
protein-markers are already considered during the treatment of triple negative breast 
cancer (TNBC)37, the main reference point for endocrine treatments is ER 
expression38. Additional surrogate markers could be used to identify high risk 
populations, which would profit from switches from standard therapies to suitable 
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chemotherapies already from the onset of the treatment, as is already part of the 
ESMO guidelines for patients with high tumor burden 13.  
MicroRNAs (miRNA) are small non-coding RNAs which are important in transcriptional 
and translational regulation of cellular processes, making them promising prognostic 
markers. As the detection in tissue, as well as in blood samples, is getting easier, 
alterations in expression levels could be used to assess aggressiveness of tumors and 
in certain cases even predict treatment response 39. A miRNA of special interest is 
miR-27a, which was shown to play a role in multiple metabolic processes and different 
cancer types. In general, miR-27a is considered tumor promoting, i.e. increasing 
cancer progression and resistance to chemotherapeutic agents, as observed in 
different cancer types including breast cancer cells 22-24. Therefore miR-27a is 
considered a potent oncomiR, whose high expression is unfavorable for patients’ 
survival in many settings, like osteosarcoma and gastric cancer 40,41. Previous studies 
suggest that miR-27a is regulating the ERα expression indirectly via ZBTB10 and the 
sp-protein family42, hence the role of miR-27a in ER-positive breast cancers is of 
interest. 
Our findings, while not objecting miR-27a’s tumor promoting effects, suggests that high 
expression of miR-27a may serve as an indicator of functional ER-expression in 
luminal A breast cancer and could therefore act as a positive marker for SERM 
response in vitro, resulting in a survival benefit as observed in vivo. 
 
2.3. Results 
2.3.1. Induction of tamoxifen resistance leads to repression of ERα and 
miRNA-27a expression 
In order to induce resistance to tamoxifen, MCF7 cells were treated with tamoxifen for 
six cycles each followed by recovery phases, as described previously43. 
The resulting resistant MCF7 cells, labeled TAM6, showed an increasing IC50 of 
approximately 1.5-fold (Figure 3 a). As loss of ERα expression is common in acquired 
resistance to tamoxifen, an analysis of ERα expression changes was performed. The 
resistant TAM6 cells showed significantly decreased levels of ESR1 mRNA (Figure 3b) 
as well as decreased ERα protein expression (Figure 3c). The transcriptional activity 
of ERα was assessed via an ERE (estrogen-receptor-response element) luciferase 
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reporter assay which indicated a significant loss of relative signaling of about 40% in 
the TAM6 cells (p < 0.05) compared to wildtype MCF7 (Figure 3d). Interestingly, the 
resistant TAM6 cells showed also a decreased expression of miR-27a (Figure 3e). 
 
Figure 3 - Induction of tamoxifen resistance leads to repression of ERα and miR-27a expression  
a) A Molecular Evolution Assay of 6 cycles tamoxifen (TAM) treatment resulted in resistant MCF7 cells, 
the TAM6 cells, with increased resistance to 20µM TAM (p < 0.001) as well as an increased IC50 value. 
b) ESR1 mRNA levels are significantly decreased by approximately 50% in the resistant cells, as shown 
by RT-qPCR (p < 0.05), c) as well as western-blot for protein levels, GAPDH was used as housekeeper. 
d) The relative luciferase signal of the ERE-reporter is significantly decreased in the resistant cells (p < 
0.05). e) Expression of miR-27a is decreased to 50% in the the resistant TAM6 cells compared to MCF7 
wildtype (p < 0.05). 
2.3.2. The interplay of miRNA-27a and ERα in a positive feedback loop 
To investigate whether miR-27a’s is able to regulate the expression of ERα, basal 
miRNA expression was analyzed in two Luminal A breast cancer cell lines, T47D and 
MCF7. Both cell lines showed expression of miR-27a. In MCF7 the miR-27a levels 
were six times higher than in T47D cells (Figure 4a). Nevertheless, ectopic 
overexpression of miR-27a showed a further increase of ERα mRNA (ESR1) in MCF7 
and T47D of 20% to 50%, respectively (Figure 4b), and a 1.3 and 2-fold increase in 
protein levels (Figure 4c). The ERE-reporter assay revealed a 40-50% increase in 
luciferase signal, indicating increased transcriptional activity of ERα (Figure 4d). These 
findings were supported by an immunofluorescence staining (Figure 4e), which 
showed that upon stimulation with estradiol the ERα localization into the nucleus is 
stronger after miR-27a overexpression compared to controls.  
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Of note, also the reintroduction of miR-27a into the low-expressing tamoxifen resistant 
TAM6 cells reactivated ERα expression and signaling as shown by a significantly 
increased ERE-luc signal of more than 50% compared to controls (p < 0.05, Figure 4f). 
 
Figure 4 - The effect of miR-27a on ER-alpha signaling in luminal A breast cancer  
a) Expression of miR-27a in the two luminal A breast cancer cell lines, MCF7 and T47D. b) 
Overexpression of miR-27a significantly increased expression of ESR1 mRNA in MCF7 and T47D (p < 
0.01), b) ERα protein, as well as c) luciferase signal of the ERE-reporter compared to scrambled control 
(p < 0.05). e) Immunofluorescence staining of ERα and DAPI showed increased localization of ERα to 
the nucleus in miR-27a overexpressing cells which were stimulated with estradiol (ES). f) Re-expression 
of miR-27a in TAM6 cells significantly increased the relative luciferase signal of the ERE-reporter 
compared to scrambled control (p < 0.05). 
 
To investigate a possible regulation of miR-27a expression by ERα activity, MCF7 cells 
were depleted of estrogen stimulation in estradiol- and phenol red free media or 
stimulated with estradiol for 48 h. The miR-27a expression was analyzed and as shown 
in Figure 5a, after the depletion of estrogen stimulation, the miR-27a expression was 
significantly decreased (p < 0.001) compared to control. Additionally, stimulation with 
estradiol showed a slight but not significant increase of miR-27a in MCF7 cells.  
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To further investigate the correlation, a stable MCF7 cell line with inducible expression 
of a short hairpin inhibitor of ERα mRNA, MCF7 shER, was generated. Upon induction 
with doxycycline for 48 h, the cells showed decreasing ERα protein of one third 
compared to uninduced control (Figure 5b). Long-term depletion of ERα by induction 
of the shER for 29 days compared to a scrambled hairpin control, showed a stable 
effect of 20% reduction of ESR1 mRNA (Figure 5c). Importantly, the ERα knock-down 
resulted also in a highly significant decrease in miR-27a expression of 30%  
(Figure 5d). These findings indicate a mutual influence of miR-27a and ERα expression 
in a positive feedback loop. Thus, a genomic analysis of the miR-27a locus was 
performed, investigating possible regulation mechanisms based on ERα transcriptional 
effects. Two different modes of transcriptional regulation were considered: Direct 
regulation of ERα via binding to known ERE structures located upstream of the miR-
27a locus, or indirect influence by predicted binding of other transcription factors, which 
are known to be regulated by ERα. Figure 5e shows the possible bindings and 
interactions in the promotor (-500/-1 bp) and the enhancer region (-30,000/-1 bp) of 
miR-27a: Two putative ERE sites were found, one in the proximal promotor with a 
match of 11/13 bases to the consensus sequence, and one in the distant enhancer 
with 12/13 matching bases. Additionally, a site for JUN in the promotor, as well as the 
co-transcription factors of ERα AP-2αA and C/EBPβ in the enhancer, were predicted 
with high stringency44,45. This analysis indicated a high probability of transcriptional 
regulation of miR-27a by ERα, consolidating the hypothesis of an important function of 
both miR-27a and ERα in the development of resistance to tamoxifen treatment.  
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Figure 5 - The effect of ERα signaling on miR-27a expression  
a) MCF7 cells that were depleted of estrogen-stimulation, showed significantly decreased expression of 
miR-27a (p < 0.001). b) Induction of shER-expressing MCF7 cells with 5µg/ml doxycycline for 48h 
decreased protein levels of ERα 30%. c) Long-term induction of shER for 4 and 29 days, significantly 
decreased ESR1 mRNA (p < 0.01), as well as d) the expression of miR-27a. e) Schematic overview of 
the promotor and enhancer region of the miR-27a locus. An analysis of possible transcription-factor 
interactions revealed three interaction partners of ERα, possibly controlling miR-27a transcription. 
 
2.3.3. Overexpression of miRNA-27a induces sensitivity towards SERM 
treatment in vitro 
While formation of resistance to tamoxifen is correlated to loss of miR-27a, the reverse 
setting of miR-27a overexpression in luminal A cell lines was of interest. In order to 
analyze the sensitivity towards the treatment, MCF7 and T47D were transfected with 
miR-27a mimics and subsequently treated with different SERMs: Tamoxifen, its active 
metabolite endoxifen as well as toremifene. As shown in Figure 6a-c, miR-27a 
sensitized MCF7 cells to all tested SERM treatments. To investigate whether the 
changes in viability induced by tamoxifen, as determined by ATP-content, were not 
only based on changes in metabolic activity, an annexin V assay was performed to 
determine ratios of induced cell death. Viability is regarded as the percentage of cells 
with negative annexin as well as propidium iodide stainings. In line with the ATP-
measurements, MCF7 with an overexpression of miR-27a showed increased 
sensitivity towards tamoxifen treatment (Figure 6d) 
Replication of this experiment with another luminal A cell line, T47D, showed similar 
results for tamoxifen, endoxifen and toremifen compared to controls (Figure 6e-g). Also 
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the rescue of miR-27a expression in the tamoxifen resistant and miR-27a-low TAM6 
cells re-sensitized the cells towards tamoxifen treatment, as seen by a significant 
decrease in viability after the treatments, compared to control (Figure 6h). Further 
validation with the annexin V assay showed that these effects are based on apoptosis 
and cell death, rather than diminished metabolism (Figure 6i). 
Together, these data showed a sensitizing effect of miR-27a to SERM treatments in 
both tested luminal A cell lines, as well as a re-sensitizing effect in tamoxifen resistant 
cells. 
 
Figure 6 - Effect of miR-27a overexpression on resistance to SERMs 
MCF7 cells with miR-27a overexpression showed significantly increased sensitivity towards treatments 
with the different SERMs as shown as viability measurement by ATP content, compared to scrambled 
control (Ctrl): a) 16µM tamoxifen (TAM), b) 12.5µM endoxifen (Endo) and c) 30µM toremifen. d) An 
annexin V-FITC assay of TAM treated MCF7 cells showed a decreased number of viable cells after miR-
27a overexpression. T47D cells with overexpression of miR-27a with e) 12.5µM TAM, f) 10µM Endo, g) 
22.5µM TOR showed significantly decreased viability, compared to scramble control. h) The resistant 
TAM6 cells were significantly re-sensitized to TAM treatment by overexpression of miR-27a shown as 
viability by ATP content, i) as also by Annexin measurements. All experiments were compared and 
normalized to a scrambled control transfection (** p < 0.01, *** p < 0.001, ****p < 0.0001) 
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2.3.4. MiRNA-27a is a putative prognostic marker for endocrine therapies in 
metastatic ER+ breast cancer  
As validation of the in vitro results, the impact of miR-27a expression on the survival of 
patients with ER-positive tumors which underwent endocrine treatment was evaluated. 
An analysis of patient data derived from the METABRIC cohort was performed utilizing 
the tool “miR power” (http://www.kmplot.com) by Lanczky et al. 46. In this analysis, 
patients were grouped according to their ER expression, as determined by 
immunohistochemistry and their status of node invasion. Patient groups with ER-
positive tumors were narrowed down to the cohort which underwent endocrine 
treatment exclusively, while no further limitations were set in groups with ER-negative 
tumors in regard of the therapy. 
As shown in Figure 7, patients with ER-positive tumors and high miR-27a expression 
had beneficial overall survival (OS) of about 20 months and a lower risk of events, 
compared to the low expressing group (N=726, HR 0.87 (0.6-1.08), p=0.15; not 
significant). The corresponding Kaplan-Meier curves show the biggest difference 
between the two groups during 100-150 months of follow up, corresponding to the 
usual follow-up care for breast cancer patients. In contrast, ER-negative breast cancer 
patients with high miR-27a expression were at approximately one third higher risk and 
had a 1.5 years lower median OS than the low expressing cohort (N=266, HR 1.33 
(0.84-2.09), p=0.22). Further differentiation of the ER-positive group to a subgroup 
which is determined as luminal A, the relative risk additionally decreased to 0.61 (0.39-
0.94) with p=0.025 (see supplemental Figure S3). 
By further differentiation of the dataset, patients with more aggressive luminal A cancer 
were investigated. Those groups were constricted to subgroups with positive lymph 
node status, indicating a higher metastatic ability of the tumor and higher tumor burden 
of the patients. In this setting, the data showed highly significant difference in the 
ER-positive group towards a beneficial effect of high miR-27a in the OS. Patients with 
low miR-27a expression had an approximately 50 months shorter survival, therefore 
decreasing the risk in the high miR-27a to 0.65 (0.47-0.9; p=0.0083). Likewise, the 
comparison in ER-negative patients showed the reverse picture: High miR-27a 
expression lead to a significant decrease in OS of about 50 months with a two-fold 
increased relative risk (HR 2.02, (1.09-0.023), p=0.023). Here, in the luminal A 
subgroup (see supplemental Figure S3) high miR-27a lead to significantly increased 
OS of about 40 months and 0.51 (0.31-0.85) relative risk (p=0.0083). Similar results 
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were seen in another cohort of luminal A patients with early breast cancer, which 
underwent tamoxifen treatment, as analyzed with the MIRUMIR tool 47 (supplementary 
Figure S4). 
These findings showed that miR-27a expression was high in aggressive tumors and 
was detrimental for patients with ER-negative breast cancer, but in the setting of ER-
positive tumors that were treated with endocrine therapies high miR-27a levels were 
an indication for a good response to the treatment and increased survival rates. 
 
Figure 7 - Clinical data shows potential of miR-27a as prognostic marker for endocrine therapies 
ER+ and ER+ metastatic breast cancer 
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2.4. Discussion 
While luminal A breast cancer is regarded as the one subtype with best prognosis and 
well established treatment options, current epidemiologic data suggest a need for 
better follow-up care of the disease, as evidently mortality of these patients is 
increasing after 5 years31. Different approaches are made to counteract bad long-term 
outcomes. Often SERM treatments are prolonged for a time of up to 10 years and 
longer or switched for different treatments with drugs of other therapeutic classes, 
usually aromatase inhibitors 31,48. Many of these approaches are associated to the 
same adverse effects as SERM treatment, i.e. cardiovascular disease and the 
substantially increased risk of secondary cancers like endometrial carcinoma 49. 
Hence, physicians are inclined to often discontinue therapies early to balance these 
risks. Still, the number of relapsing patients with therapy resistant tumors is high and 
therefore there is an urgent need for personalized treatment options to maximize 
efficacy of therapies while decreasing the adverse effects. MiRNAs are a class of 
potential markers, which show fine-tuned expression patterns in tissues, as well as 
offer the possibility to analyze their expression directly from blood samples as 
circulating miRNAs39. 
MiR-27 plays an ambivalent role in cancer. On the one hand, it is known to increase 
proliferation and metastasis in patients22, in some cases even assumed to regulate 
chemoresistance 50. This aspect makes it an interesting marker for numerous cancer 
types, like colon and esophageal cancer and also certain types of breast cancer, in 
order to adjust treatments and therapy regimes accordingly 22,23,50. In the analysis of 
the METABRIC datasets, two cohorts of patients with ER-negative tumors, which 
consequently did not receive endocrine treatments, showed significantly worse 
outcomes for patients with high miR-27a expression. This result is in line with the 
discussed role of miR-27a as oncomir, inducing negative effects on patient survival. 
On the other hand, the in silico analysis of both the METABRIC and MIRUMIR datasets 
revealed that miR-27a expression is a predictor of beneficial breast cancer patient 
survival, in a defined subgroup of ER-positive tumors treated with endocrine agents. 
Multiple explanations can be considered for this ambivalence. First, due to the positive 
bidirectional feedback loop between miR-27a and ERα, the miR-27a expression may 
function as a surrogate marker for the ERα expression. MiR-27a was described to 
upregulate ERα expression, as observed in the current study and was previously 
reported, based on miR-27a inhibition of ZBTB10 and resulting increase of the 
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expression of the sp-protein family42. In this case, higher levels of ERα, based on 
increased miR-27a expression, could increase the susceptibility for SERMs and 
therefore improve the eradication of the tumor. While an increase of drug targets is 
often discussed as resistance mechanism, different studies suggest that SERM 
antitumor effects are based not only on inhibition of the estrogen signaling, but 
additionally on induction of maspin or of oxidative stress, which result of interaction 
with the receptor 51,52. Therefore, an increased number of SERM targets could correlate 
with the induced damage in the tumor. 
Additionally, our data showed that stimulation with or the deprivation of estradiol, as 
well as a direct knock-down of ERα, showed identically directed impact on miR-27a 
expression, as was also reported in a genomic expression study previously 53. The in 
silico analysis of the promotor and enhancer region revealed multiple potential sites of 
transcriptional regulation of miR-27a via ERα, e.g. by direct translational effects based 
on EREs or upregulated transcription factor activity downstream of the ER-signaling 
pathway, like JUN. 
Thus, high miR-27a levels may act as surrogate read-out for a high ERα translational 
activity in the tumor, likely with crucial cancer promoting effects due to ERα’s role in 
cell cycle and proliferation54. This could explain the higher impact on cancer cell 
survival resulting from ERα inhibition.  
Both of these discussed mechanisms do not contradict miR-27a’s role as oncomiR, as 
increase of ER-activity leads to higher proliferation and metabolic activity in the cells54.  
In fact, the in vitro viability data suggest that treatments with tamoxifen and toremifen 
are significantly more effective in eradicating these potentially more aggressive tumors, 
underlined by the finding that the beneficial prognostic effect of miR-27a is highest for 
ER-positive tumors which spread to lymph nodes. 
Besides acting as predictor for an enhanced response to SERM treatments, the 
observed loss of miR-27a may also function as indicator of resistance to the therapy, 
as observed in the TAM6 cells. Treatment with TAM for six rounds in the course of 
multiple weeks, caused the formation of a considerable resistance, accompanied by 
the loss of miR-27a, as was also demonstrated by Ye et al 55, showing increased miR-
27a expression after generation of TAM resistant cells.  
Many mechanisms are discussed for resistance development to tamoxifen. One 
obvious effect which may account for up to 17-28% of acquired resistance56, may be 
the loss of ERα, rendering the cancer cells independent of estrogen, based on CpG 
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island methylation of the ER-promotor57. As no analysis of methylation patterns was 
performed on the TAM6 cells, it is possible that partial methylation of the ESR1 
promotor occurred and therefore affected changes in ERα and miR-27a expression.  
In addition, the occurrence of mutations of the ER-gene were reported, which are not 
influencing the ERα expression, but were observed to have no estrogen mediated 
translational activity while appearing as ER-positive in immunohistological stainings 58. 
In this case, miR-27a may be a valuable indicator of functional ERα expression, as ER-
positive tumors with low miR-27a expression might inherit a less functional ERα 
translational activity and thus decreased response to SERMs.  
Taken together, miR-27a expression correlates with functional ERα expression and 
may therefore act as surrogate read-out for a frequent resistance mechanism. 
MiRNA screening can play an important part in improving patient outcomes by enabling 
tailored treatments and personalized medicines for cancer. A screening of different 
miRNAs, including miR-27a in blood plasma of breast cancer patients was performed 
previously 59. In the study of Jurkovicova et al. miR-27a was shown to be one of the 
modified miRNAs in the analysis of plasma samples from the patients. The data 
indicates that miR-27a expression may be used as marker for invasive breast cancers 
or carcinomas in situ. Further studies need to be conducted to prove whether miR-27a 
expression is a prognostic marker for therapeutic response also in blood plasma. 
Taken together, our data suggests and encourages further studies of miR-27a as 
marker for SERM response in the clinics. Patients with ER-positive tumors with high 
miR-27a expression currently already receive suitable treatment with adjuvant 
tamoxifen, if treated according to the guidelines13. However, patients in the same 
setting with miR-27a low tumors may display resistance to the treatment, either initially 
or due to acquired resistance in the long-term. These patients would benefit most of 
an analysis of miR-27a levels. 
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2.5. Material and methods 
Reagents 
Puromycin dihydrochloride (cat. P8833), Tamoxifen (cat. T5648), Endoxifen (cat. 
E8284), Toremifen (cat. T7204) and Estradiol (E1024) were obtained from Sigma-
Aldrich.  
Cell culture 
MCF7 were acquired from cell line service (Eppelheim, Germany), grown at 37 °C and 
5 % CO2 in high glucose DMEM (Sigma) supplemented with 10 % fetal calf serum (FCS 
/ Gibco). TAM6 as resistant clone were generated from parental MCF7 by six rounds 
of treatment with tamoxifen as described before43 and cultured like MCF7. T47D were 
acquired from ATCC, grown at 37 °C and 5% CO2 in RPMI-media (Sigma).  All cells 
were routinely tested and confirmed as mycoplasm free. 
Overexpression of miR-27a 
Overexpression experiments were performed by transfection of a miR-27a mimic 
(miRIDIAN Human hsa-miR-27a 3p, Dharmacon) and miRIDIAN Mimic Negative 
Control #1 (Dharmacon) with K2 transfection reagent (Biontex, Germany) according to 
the manufacturer’s protocol. Cells were seeded in 6-well plates to 80% confluence 
depending on the experiment kept in 6-well or seeded 24 h after transfection for 
following experiments. 
miRNA quantitative RT-PCR 
Approximately 600,000 cells were harvested and total RNA isolated from cells using 
Total RNA Kit, peqGOLD (VWR). cDNA synthesis was carried out by a microRNA 
specific reverse transcription and detection with the qScript microRNA cDNA Synthesis 
Kit and PerfeCta SYBR Green SuperMix (Quanta Biosciences) with RT-PCR detection 
on a LightCycler 480 (Roche). The expression of miR-27a was normalized to miR-191, 
using the 2-∆CT or 2-∆∆CT method. The primers used for analysis were for miR-27a: 
GCCGTTCACAGTGGCTAAG and for miR-191: GCGCAACGGAATCCCAAAAG 
mRNA quantitative RT-PCR 
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RNA was extracted utilizing the Total RNA Kit, peqGOLD (VWR) as by manufacturer’s 
instructions. Translation to cDNA was performed utilizing the qScript cDNA synthesis 
kit (Quanta Bioscience) as by manufacturer’s protocol.  
Analysis of expression was performed with the Lightcycler 480 (Roche) and the 
Universal Probe Library (Roche) with following probe and primer (forward/reverse) 
combinations: 
ESR1 Fwd:ATCCACCTGATGGCCAAG Rev:GCTCCATGCCTTTGTTACTCA; Probe #17  
GAPDH Fwd: TCCACTGGCGTCTTCACC Rev:GGCAGAGATGATGACCCTTTT; Probe #45 
The expression of ESR1 was normalized to GAPDH, using the 2-∆CT or 2-∆∆CT 
method.  
ER-signaling via ERE-luc reporter 
3X ERE TATA luc was a gift from Donald McDonnell (Addgene plasmid # 11354). 
Transfection was performed in 6-well with cells grown to 80% confluence with K2 
transfection reagent (Biontex, Germany) according to the manufacturer’s instructions. 
After 24 h cells were seeded in 96-well plates and luc-measurements were performed 
as described previously28. 
Generation and stimulation of TRIPZ-shER MCF7 
MCF7 cells were transducted with a 2nd generation lentiviral system generated with the 
plasmids pCMV-dR8.2 dvpr and pCMV-VSV-G, which were a gift from Bob Weinberg 
(Addgene plasmid # 8454 and #8455) and a doxycycline-inducible TRIPZ-shER 
construct, which was a gift from Yunus Luqmani, Kuwait. For control, cells were 
transducted with a scramble hairpin, the TRIPZ-shCtrl construct (ThermoFisher). 
Western blot analysis and immunofluorescence  
Cells were cultured in a 6 well plate for 48h after transfection / stimulation, lysis, gel 
and blotting were performed as described previously27, with the following primary 
antibodies: Estrogen Receptor-α (sc-543), Actin (sc-1616, Santa Cruz) and GAPDH 
(14C10, Cell Signaling). Immunofluorescence stainings were performed as described 
previously60, -ES cells were cultured for the time of the experiment in phenol-red-free 
media with 10% charcoal stripped FCS (F6765 , Sigma), +ES cells were stimulated 
with 3,6 µM estradiol for 1h before fixation. 
Analysis of transcription factors in promoter regions of found genes 
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For the analysis of the promoter region of the miR-27a locus, the sequence was 
retrieved from the RefSeq-Database (https://www.ncbi.nlm.nih.gov/refseq/ as of 
January 2018) in order to identify the +1 position. Assuming the +1 position as starting 
site of transcription, 500 nucleotides upstream were defined as the proximal promoter. 
The enhancer region was defined as the genomic sequence 30,000 base pairs 
upstream of the +144. Then, for analysis of possible promoter sequences, ALGGEN61 
software was used, the analysis was performed with the highest stringency. Analysis 
of ERE-sites were performed by manual alignments of the consensus sequence and 
known variances that were previously discussed62. 
Treatment with SERMs and relative viability assays 
Stock solutions of TAM, ENDO and TOR were prepared in DMSO with a concentration 
of 20mM. Dilutions were prepared freshly in according media, controls contained 
appropriate amounts of DMSO. Treatments were performed 48 h after stimulation / 
transfection for 48 h. Relative viability as ATP-content was assessed by Celltiter-Glo 
(Promega) according to manufacturer’s instructions. 
Annexin V assay 
The cells were cultured and treated as described above. Samples were harvested, and 
analyzed with the Annexin V-FiTC Apoptosis Detection Kit Plus (BioVision) according 
to the manufacturer’s protocol. Measurement was performed using CyAn ADP 
Flowcytometer (Dako Cytomation / Beckmann) and FlowJo 7.6.5. (TreeStar). 
In silico analysis of patient data 
Patient survival data, treatment information and expression of ERα / miR-27a was 
acquired from the database of kmplot software (http://www.kmplot.com46). Analysis for 
miR-27a was based on data from the METABRIC study (syn1688369)35. 
Statistical analysis  
Results are expressed as the mean ± SD of at least three replicas, if not stated 
otherwise. All experiments were conducted three times independently, one 
representative example is depicted. Software GraphPad Prism v6 and SigmaPlot 11 
were utilized for the analysis of the data.  
Data availability 
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The data that support the findings of this study are available from the corresponding 
author upon reasonable request.  
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3. A proteomic analysis of an in vitro knock-out of miRNA-200c 
The following sections are directly adapted from the original publication, which was 
finally published as Ljepoja et al., Sci Rep. 2018 May 2;8(1):6927. 
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3.1. Abstract 
Loss of miR-200c is correlated to advanced cancer-subtypes due to increased EMT 
and decreased treatment efficacy by chemotherapeutics. As miRNAs regulate a 
multitude of targets, the analysis of differentially expressed proteins upon a genomic 
knock-out (KO) is of interest. In this study, we generated a TALENs KO of miR-200c 
in MCF7 breast cancer cells, excluded its compensation by family-members and 
evaluated the impact on the proteome by analyzing three individual KO-clones. We 
identified 26 key proteins and a variety of enrichments in metabolic and cytoskeletal 
pathways. In six of these targets (AGR2, FLNA/B, ALDH7A1, SCIN, GSTM3) the 
differential expression was additionally detected at mRNA level. Together, these 
alterations in protein abundance accounted for the observed biological phenotypes, 
i.e. increased migration and chemoresistance and altered metabolism, found in the 
miR-200c-KO clones. These findings provide novel insights into miR-200c and pave 
the way for further studies 
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3.2. Introduction 
MicroRNAs (miRNAs) are short non-coding RNAs which are known to regulate protein 
expression at the translational level via base pairing to mRNA or by induction of mRNA 
decay26,63. Since their discovery, miRNAs have had a tremendous impact on our 
understanding of physiology and pathophysiology, leading to ever increasing efforts to 
discover miRNA genes, their function and targets1,64. MiRNAs are important for a broad 
spectrum of biological processes, such as embryonic development, immune 
differentiation, metabolism and cardiac function65-68. On the other hand, their aberrant 
expression is involved in a vast number of diseases, such as diabetes and 
cancer65,69,70. Therefore, miRNAs are promising tools as biomarkers or therapeutic 
agents71.  
An important group of miRNAs in the context of cancer research is the miR-200 family, 
consisting of miR-200a, miR-200b, miR-200c, miR-141 and miR-429. Many family 
members are known to play a role in a large variety of biological processes like 
Epithelial to Mesenchymal Transition (EMT), cell invasion, proliferation, metastasis, 
apoptosis, autophagy, and therapy resistance in several cancer types26,72-76. MiR-200c 
is the most prominent member in tumorigenesis, as its role in several hallmarks of 
cancer, such as EMT, chemoresistance, migration and stemness26,77, was already 
described. Although the involvement of miR-200c in these processes was 
demonstrated, many underlying mechanisms and players remain unknown26, 
especially in controversially discussed processes like chemoresistance or 
proliferation26-28,78,79. 
In our previous work, we were able to show the involvement of miR-200c in sensitizing 
breast cancer cells to doxorubicin, via regulating BMI1 and TRKB27 as well as the direct 
interaction of miR-200c with the mRNA of the prominent oncogene KRAS28. 
The vast majority of the studies analyzing the biology of miR-200c utilizes short-term 
inhibition approaches making use of LNAs or antagomirs, but omitting the impact of 
miR-200c depletion in the long-term27,80,81. The latter reflects the loss of miR-200c 
expression in a tumor, as is frequently observed in the clinics82,83. Thus, analyzing the 
knock-out (KO) of miR-200c leads to novel insights into miR-200c’s role in advanced 
breast cancer.  
With current genome editing tools like TALENs (Transcription Activator-Like Effector 
Nucleases) and CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic 
Repeats)30,84 a revolution in many fields of gene research was initiated. While both 
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tools have different properties and demand different strategies, they also equally 
harbor high potential for research of non-coding genes, like miRNAs. TALEN are fusion 
proteins that induce a double strand break in the DNA, but have to be designed as 
pair, specifically targeting the desired genomic site. The nuclease-activity will cause a 
double strand break (DSB) which can be repaired on the hand by error prone Non-
Homologous End Joining (NHEJR), in most cases leading to an indel formation and 
thus to the knock-out of the gene. On the other hand Homologous Recombination (HR) 
results in successful repair of the DSB30,85.  
CRISPR-Cas9 is based on the nuclease-activity of Cas9, but the targeting is initiated 
by short-guiding RNAs (sgRNA) and is limited to genomic sites with a protospacer 
adjacent motif (PAM). CRISPR approaches usually lead to a double strand break and 
only one sgRNA needs to be designed29,84,86. 
In this study, we utilized TALENs for a genetic KO of miR-200c, due to its flexibility to 
target any genomic sequence. This approach allowed us to develop a long-term in vitro 
model of miR-200c depletion (KO) in MCF7 breast cancer cells. With a subsequent 
proteomic analysis, we were able to gain novel insights to changes in the proteome, 
i.e. differentially expressed proteins, resulting from the absence of only 22 non-coding 
basepairs of the miR-200c. 
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3.3. Results 
3.3.1. A miRNA-200c knock-out - strategy and validation 
To generate the miR-200c KO, we chose to genetically disrupt the drosha processing 
site. Generally two options for genomic editing were available – CRISPR/Cas9 and 
TALENs. While a PAM-sequence was present in the drosha processing site, suitable 
sgRNAs were designed with the CRISPR-design tool87 but resulted in 60-75 
off-targets, amongst them 6-9 in coding regions. Utilizing a Cas9-Nickase would result 
in lower off-targets, but it was not possible to design a pair inducing a site-specific 
mutation within the limited number of base-pairs of the drosha-site. Therefore, we 
chose a pair of TALENs to disrupt miR-200c 3p gene expression by targeting the 
flanking regions of the drosha processing site as described previously88. Eventually we 
sought to induce a double strand break in the vicinity of the drosha processing site 
(Figure 8a). MCF7 cells were chosen as model for an epithelial breast cancer cell line 
with high miR-200c expression27. A single cell dilution was performed, and clones were 
selected to sequence indel formation at the genomic locus of the miR-200c drosha site. 
Three of the monoclonal cell lines, namely M1, M2 and M3 showed deletions in both 
alleles of the miR-200c gene which were located in vicinity of the drosha processing 
site (i.e. homozygous KO of miR-200c). One clone (MCtrl) showed a heterozygous 
mutation (Figure 8b). 
A qPCR-measurement of miR-200c expression of M1, M2 and M3, confirmed the 
knock-out of the miR-200c gene (Figure 8c). The heterozygous mutations in MCtrl had 
no significant effect on the miR-200c expression, as levels were comparable to MCF7 
wild-type (p>0.05). Therefore, besides wild-type MCF7, MCtrl was considered as 
additional control for further analysis. 
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Figure 8 - miR-200c genetic TALEN target sequences and knock-out confirmation.  
a) The miR-200c gene is located at chromosome 12p13, TALENs were designed to target miR-200c 3p 
drosha processing site. b) Genomic DNA was extracted from MCtrl and M1, M2 and M3 clones, 
afterwards the miR-200c gene was amplified by PCR to perform sequencing of the miR-200c loci; MCtrl 
shows a heterozygous mutation while M1, M2 and M3 show various indels in proximity of the miR-200c 
3p drosha processing site on both alleles. c) MCF7, MCtrl, M1, M2 and M3 miR-200c expression levels 
were analyzed by quantitative RT-PCR. Expression of miRNAs is shown as mean of three independent 
experiments ± SD .ns: no statistical difference, p>0.05, one-way ANOVA post hoc Bonferroni. 
3.3.2. Unchanged expression of miR-200 family members 
To investigate possible compensation effects of the knock out, we analyzed the 
expression levels of the other miR-200c family members. The genomic loci are 
comprised of two genomic clusters, one located at chromosome 1p36 including miR-
200a, miR-200b and miR-429, and chromosome 12p13 containing miR-200c and miR-
14126. MiR-200c shares the same seed region with miRs 200b and 429 (Figure 9a).  
Subsequently, a qPCR analysis of the expression of all family members was 
performed. 
This data showed that miR-200c is the family member with highest expression in 
MCF7. Further analysis revealed that no family member was compensating for the loss 
of miR-200c by an increase of expression and no general upregulation of all family 
members was observed (p>0.05) compared to the control group (MCF7 and MCtrl).  
Of note, also the expression levels of miR-141 remained similar, i.e. not influenced by 
the KO of miR-200c, despite the localization in the same polycistronic unit (Figure 9b). 
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The knock-out of a miRNA is fundamentally different to its short term inhibition, giving 
the cells more time to compensate the loss of miR-200c. Therefore, late compensatory 
mechanisms were ruled out by re-evaluation of the expression of miR-200c family 
members at a late cell passage number. Compared to earlier passages, the data 
showed no remarkable changes in the different clones over time (p=0.896, Figure 9c). 
The slight increase of miR-141 is not significant. 
 
Figure 9 - Expression of miR-200 family members among the KO clones.  
a) The miR-200 family is distributed on two chromosomes; miR-200b, miR-200a and miR-429 are 
located on chromosome 1p36.33 and miR-200c and miR-141 are located on chromosome 12p13.31. 
miRs with the same seed region are colored in tones of orange or blue respectively. b) MCF7, MCtrl, 
M1, M2 and M3 were analyzed for miR-200c, miR-141, miR-200a, miR-200b and miR-429 relative 
expression levels by quantitative RT-PCR. c) Cells from passage 10 and passage 23 were compared 
regarding their miR-200c, miR-141, miR-200a, miR-200b and miR-429 relative expression levels via 
quantitative RT-PCR. Expression of miRNAs is shown as mean ± SD of three independent replicas. ns 
means no statistical difference, p>0.05, three way ANOVA post hoc Bonferroni. 
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3.3.3. Proteomic analysis of three individual KO clones results in 26 novel 
targets 
To evaluate the effect of the miR-200c KO on a wide range of proteins, a proteomic 
approach was chosen ( 
Figure 10a):  
All clones (M1, M2, M3, MCtrl), as well as wild-type MCF7 cells were harvested in three 
replicas (A/B/C), and subsequently, proteomic data analysis was performed, resulting 
in a set of 1736 identified proteins. For the following analysis, we chose to narrow the 
set down to proteins that were identified in every single measurement.  
This filtering resulted in a subset of 675 proteins. On this subset, a principal component 
analysis (PCA) was performed to investigate the similarity of the clones and replicas.  
Figure 10b shows a general trend of grouping of the replicas (with exception of MCtrl C) 
as well as a closer relation between the KO-clones M1, M2 and M3 and the controls 
MCF7 and MCtrl, respectively. A similar behavior is seen in a cluster analysis, as 
shown in the Supplement S 1. For statistical evaluation of differentially expressed 
proteins a Volcano plot analysis was performed ( 
Figure 10c), comparing the expression of the KO-clones M1, M2 and M3 (KO) to the 
controls MCF7 and MCtrl (Ctrl). This analysis revealed nine proteins with significant 
changes in regulation as shown in Table 1. 
To investigate effects on single-clone level, a further T-test with the same parameters 
was performed, comparing each KO-Clone (M1, M2 or M3) to the grouped controls 
(e.g. M1 vs. MCtrl and MCF7). The analysis revealed 17 significant hits, as shown in 
Figure S2 and summarized in Table 2. Here, M2 is pointed out as most diverse from 
the controls with 14 proteins being differentially expressed, while the two other clones 
show only statistical difference in one or six proteins for M1 and M3, respectively 
(Supplement S 2). 
Next, to further analyze targets which may have had changes in expression in 
response to the miR-200c KO but have not been detected in the previous analysis, we 
searched for proteins that were not detected in the KO-group, but were found in the 
control-group (found at least 3 times in Ctrl, not at all in the KO). These proteins were 
termed “OFF”. Vice versa, “ON” proteins display no expression in the control-group but 
are expressed in the KO-group (at least 5 times in KO, but not in Ctrl). Table 3 lists the 
three targets gaining expression after knock-out (ON) and the two proteins losing 
expression (OFF). 
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The 26 targets shown in Table 1, 2 and 3 were grouped according to their main function 
as stated by the Uniprot-Database89. As shown in  
Figure 10d, more than half of the proteins are found in migratory processes and 
metabolism (45% and 17% respectively), while other functions are detoxification (10%) 
and apoptosis (11%), with remaining 17% of proteins, with no known function. 
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Table 1 - Targets with significant difference between both groups – M1 and M2 and M3 vs MCF7 
and MCtrl 
 
  
Protein Gene p-Value fold change Expression Function 
Anterior gradient protein 2 
homolog 
AGR2 6.36x10-3 0.59 down Migration 
Filamin-A FLNA 4.32x10-5 1.31 up Migration 
Filamin-B FLNB 1.20x10-5 1.41 up Migration 
Glutathione S-transferase 
Mu 3 
GSTM3 1.43x10-5 3.54 up De-Tox 
Pyridoxal kinase PDXK 2.27 x10-3 0.53 down Metabolism 
4F2 cell-surface antigen 
heavy chain 
SLC3A2 1.25 x10-4 2.00 up Apoptosis 
Spectrin alpha chain, non-
erythrocytic 1 
SPTAN1 3.26 x10-4 0.73 down Migration 
Tropomyosin alpha-1 chain TPM1 3.74 x10-3 1.93 up Migration 
UDP-glucose 6-
dehydrogenase 
UGDH 7.10 x10-3 0.39 down Migration 
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Table 2 - Targets with significant difference between control and at least one clone: M1 or M2 or 
M3 vs. MCF7 and MCtrl 
Protein names Gene p-Value fold increase Expression Function 
Anterior gradient protein 2 
homolog 
AGR2 
M2 vs Ctrl M2 vs Ctrl 
down Migration 
2.82 x10-4 0.397 
Alpha-aminoadipic 
semialdehyde 
dehydrogenase 
ALDH7A1 
M2 vs Ctrl M2 vs Ctrl 
up De-tox 
4.69 x10-4 1.96 
Carbonic anhydrase 2 CA2 
M2 vs Ctrl M2 vs Ctrl 
down Unknown 
4.07 x10-3 0.361 
Src substrate cortactin CTTN;EMS1 
M2 vs Ctrl M2 vs Ctrl 
down Migration 
4.67 x10-4 0.743 
Aspartate aminotransferase GOT2 
M3 vs Ctrl M3 vs Ctrl 
down Metabolism 
1.38 x10-4 0.556 
Glutathione S-transferase 
Mu 3 
GSTM3 
M1 vs Ctrl M1 vs Ctrl 
up De-tox 
6.03 x10-5 2.48 
M2 vs Ctrl M2 vs Ctrl 
1.50 x10-7 6.17 
M3 vs Ctrl M3 vs Ctrl 
1.21 x10-5 2.91 
Heat shock protein HSP 90-
alpha 
HSP90AA1 
M2 vs Ctrl M2 vs Ctrl 
up Metabolism 
4.64 x10-4 1.39 
D-3-phosphoglycerate 
dehydrogenase 
PHGDH 
M2 vs Ctrl M2 vs Ctrl 
up Metabolism 
6.57x10-3 1.89 
Kynureninase KYNU 
M2 vs Ctrl M2 vs Ctrl 
up Metabolism 
1. x10-3 1.61 
DNA replication licensing 
factor MCM4 
MCM4 
M2 vs Ctrl M2 vs Ctrl 
down De-tox 
2.12 x10-4 0.761 
Ras-related protein Rab-14 RAB14 
M2 vs Ctrl M2 vs Ctrl 
down Migration 
1.23 x10-5 0.595 
SH3 domain-binding glutamic 
acid-rich-like protein 
SH3BGRL 
M3 vs Ctrl M3 vs Ctrl 
up Migration 
4.01 x10-5 1.85 
4F2 cell-surface antigen 
heavy chain 
SLC3A2 
M2 vs Ctrl M2 vs Ctrl 
up Apoptosis 
7.09 x10-6 2.91 
M3 vs Ctrl M3 vs Ctrl 
6.42 x10-4 1.71 
Triosephosphate isomerase TPI1 
M3 vs Ct M3 vs Ctrl 
down Metabolism 
7.95x10-5 0.69 
Tropomyosin alpha-1 chain TPM1 
M2 vs Ctrl M2 vs Ctrl 
up Migration 
4.76 x10-3 2.71 
UDP-glucose 
6-dehydrogenase 
UGDH 
M2 vs Ctrl M2 vs Ctrl 
down Migration 
3.67 x10-6 0.155 
M3 vs Ctrl M3 vs Ctrl 
3.28 x10-3 0.533 
Tryptophan-tRNA ligase WARS 
M2 vs Ctrl M2 vs Ctrl 
up De-tox 
1.20 x10-3 1.58 
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Table 3 - Targets detected in just one of the groups: M1 and M2 and M3 OR MCF7 and MCtrl 
Protein Gene Expression Function 
N-acetylserotonin O-
methyltransferase-like protein 
ASMTL ON Unknown 
Serine/threonine-protein 
phosphatase PP1-gamma 
catalytic subunit 
PPP1CC OFF Unknown 
Apoptosis-associated speck-like 
protein containing a CARD 
PYCARD OFF Apoptosis 
Regulator of microtubule dynamics 
protein 1 
RMDN1 ON Migration 
Adseverin SCIN ON Migration 
 
 
 
Figure 10 - Proteomic analysis of three different KO clones (next page) 
a) Schematic overview of the experimental procedure to generate three different clones. Each clone 
was measured in independent replicas b) Principal component analysis of the measurements, KOs are 
shown in red, Ctrls in blue c) Volcano plot analysis of grouped controls: (MCF7 WT A/B/C and MCtrl 
A/B/C) vs. (M1 A/B/C and M2 A/B/C and M3 A/B/C), N=675 with 250 randomizations, FDR 0.05 and S0 
of 0.1 d) Percentage of main functional pathways of targets in Tables 1, 2 and 3, as derived from the 
Uniprot-Database e) Analysis for possible seed-interaction of miR-200c with the targets of Tables 1,2 
and 3 and further analysis of not-directly regulated targets for binding of transcription factors with 
predicted miR-200c regulation, see also Supplemental Table S 3: f) Validation of mRNA expression with 
grouped statistical analysis (M1 and M2 and M3 vs MCF7 WT and MCtrl, N= 9 (KO) / 6 (Ctrl)) for the 
anterior gradient protein 2 homolog, aldehyde dehydrogenase 7 family member A1, filamin A and B, 
glutathione S-transferase M3 and adseverin, *p<0.05 ***p<0.001 **** p< 0.0001 
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3.3.4. Analysis of targets for miRNA-200c regulation 
To evaluate whether the targets are directly regulated by miR-200c, the genes were 
analyzed for binding sites with the TargetScan database. One fifth of the proteins 
harbor a potential targeting site (8mer or 7mer-m8/A1 seed-region match) in their 
3'UTR. For the remaining 21 genes, a possible promotor binding site of miR-200c 
regulated transcription factors was investigated. This analysis revealed that 62 % of 
the genes without binding site may be indirectly regulated by miR-200c: The promotor 
region of these genes contains at least one putative binding site for a transcription 
factor which is potentially regulated by miR-200c ( 
Figure 10e and Supplemental Table S 3). 
Further, we measured whether the differential protein-levels resulted from changes of 
the mRNA levels. Therefore, we compared mRNA levels of the single clones to their 
proteomic data each each (see Supplement S 3). For six targets alterations n protein 
abundance were reflected at the mRNA level ( 
Figure 10f).  
AGR2, the anterior gradient protein 2 homolog, was found to be statistically significant 
differentially expressed in the proteomic analysis in Table1. The mRNA expression 
correlates with the protein expression from the proteomic approach and the grouped 
analysis, i.e. M1 and M2 and M3 vs MCF7 WT and MCtrl, showed an almost four-fold 
increase with a highly significant difference between KO and Ctrls respectively 
(p<0.0001). Furthermore, aldehyde dehydrogenase 7 family member A1, ALDH7A1’s 
protein expression changed significantly in a part of the clones, but on mRNA it shows 
highly significant (p<0.0001) increased expression of 43%. Additionally, Filamins FLNA 
and FLNB were found to be significantly changed on protein level (Table 1). Again, on 
mRNA level both filamins show a significant (p=0.0004 / p=0.0003) increase of 44% 
and 59% in FLNA and FLNB respectively. Glutathione S-transferase Mu3 shows an 
increase in the mRNA expression compared to the controls (p=0.138). SCIN, adseverin 
protein from the “ON” target list (Table 3), also showed a four-fold increase in the KO 
compared to the controls (p=0.0004). Taken together in these six cases, the mRNA-
measurements are indicating a regulation of these targets on mRNA level.  
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3.3.5. The KO of miRNA-200c results in changes in cellular processes and 
pathways 
For a broader analysis of changes in biological processes and pathways, the original 
dataset was filtered for proteins that appeared at least three times in at least one group 
(i.e. three times in KO or Ctrl), this resulted in a new subset of 1243 proteins. Missing 
values were replaced by the imputation algorithm of Perseus. After a two tailed t-test 
comparing KO to Ctrl, all proteins with p<0.05 were analyzed with the DAVID functional 
gene annotation tool90,91 with the GoTerm BP (Biological Processes) database (N=118, 
Figure 11a). 
The majority of functional annotations was categorized to BP1 cellular process (92), 
metabolic processes (72) and cellular component biogenesis (26). A detailed view on 
the processes is showing the top most frequent sub-classifications according to the 
number of attributed genes in GoTerm BP FAT. Prominent processes involve 
intracellular transport, translation and oxidation reduction as well as macromolecular 
complex assembly and subunit organization. These findings indicate a broad influence 
of miR-200c on essential processes.  
Moreover, a Gene-Set Enrichment Analysis of the whole dataset after imputation 
(N=1243) was performed against GO and KEGG databases. The global Enrichment 
Score (ES) histogram revealed that miR-200c knock-out resulted mainly in the 
inactivation of pathways, as shown by an accumulation of negative ES (Figure 11b). 
For depicting exemplary pathways, we chose KEGG pathway annotations. Enriched 
pathways (Supplemental Table S 1) contain mainly metabolic processes like oxidative 
phosphorylation citrate cycle and glycolysis, or cytoskeletal organsiation as shown in 
changes in focal adhesion (Figure 11c). Negative pathway enrichment was observed 
in adherens junctions and tight junctions, regulation of actin skeleton as well as other 
metabolic pathways like purine metabolism and decrease in the cell cycle (Figure 11d 
and Supplemental Table S 1). Heatmap analysis of the GSEA (Supplement S 4 and 
Supplement S 5) show a high occurrence of table 1 and 2 targets in all these pathways.  
Taken together, the GSEA findings indicate an increase in metabolic pathways, which 
also may increase de-toxification in the cells as well as numerous de-regulations in 
cell-cell contacts and cytoskeletal organization, which may lead to increased 
metastatic potential. 
  
3. A proteomic analysis of an in vitro knock-out of miRNA-200c  
Dissertation - Bojan Ljepoja | 39 |  
 
Figure 11 - Bioinformatic analysis of the proteomic dataset  
a) Targets for DAVID 6.7 analysis with the GOterm BP database were chosen from whole dataset for 
every protein with p<0.05 after student’s t-test KO vs Ctrl b) Distribution of ES Scores in a GSEA of KO 
vs Ctrl with Gene Ontology (c5.all.v5.2) and KEGG (c2.cp.kegg.v5.2) reference database c) GSEA 
Enrichment-Plot analysis of the whole dataset shows two exemplary KEGG pathways. Oxidative 
phosphorylation and focal adhesion showing overexpression while d) cell cycle and regulation of actin 
cytoskeleton are being down regulated 
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3.3.6. Biological assays reveal the impact of miRNA-200c KO on EMT, 
chemoresistance and metabolism 
To confirm the biological relevance of the data, different in vitro assays were performed 
utilizing the clonal cell lines (KOs and MCtrl). The metabolic activity was assessed by 
measuring NAPD(H)-turnover via MTT assay over the course of 72h. All clones 
showed a significantly higher turnover (***p<0.001 for M1 and **p<0.01 for M2 
and M3), either due to increased metabolic activity or higher proliferation (Figure 12a). 
The effect of change of resistance to chemotherapeutics was analyzed by treating the 
cells with doxorubicin (DXR) analyzing relative viability via the Celltiter-Glo assay 
(Figure 12b). The strongest effect was observed in M2, which was almost 4-times 
higher than MCtrl. Still, also all other clones show a highly significantly increased 
viability and therefore higher resistance to chemotherapeutics (p<0.0001). 
Previously described de-regulations in cell-cell contacts and cytoskeleton were 
analyzed by investigation of colony-formation abilities as well as of the migratory 
potential. A significant increased colony area (p<0.05) after seven days was observed 
in the KO cells (Figure 12c and supplemental figure S7). The live imaging experiment 
with single cell tracking (20h, N=30), as shown in Figure 12d, indicates that the 
KO cells show a tendency of migrating further and faster than Ctrl, with the differences 
between M2 and M3 to Ctrl being statistically significant (p<0.05) and M1 to Ctrl highly 
significant (p<0.0001) (additional information in Supplement S 6). While these results 
indicate EMT, well-known mechanisms, like activation of ZEB1/2 or Vimentin were not 
detected and E-cadherin levels were not changed (Supplement S 8).  
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Figure 12 – Biological data to validate predicted phenotype 
a) Analysis of relative increase of metabolic activity via MTT-Assay, normalized to each starting point , 
***p<0.001 for M1 and **p<0.01 for M2 and M3 compared to MCtrl, N=4, two-way ANOVA with Dunnett’s 
multiple comparison b) Treatment with 1 µM doxorubicine for 48h and analysis of viability as by CTG 
assay , N=6, ****p<0.0001 compared to Ctrl, two-way ANOVA with Bonferroni’s multiple comparison) c) 
Analysis of colony forming abilities via the clonogenic assay shows a significantly higher colony area in 
the KOs after seven days of incubation, student’s t-test, p<0.05, N=3/9, images in Supplement S 7d) 
Single cell tracking measurement for evaluation of migratory potential, displayed as accumulative 
distance after 20 h, N=30, ****p<0.0001, *p<0.05 compared to MCtrl, one-way ANOVA with Dunnett’s 
multiple comparison after outlier test, velocity displayed in S6). 
 
 
Figure 13 - Summary of important pathways and biological phenotypes, with targets from Tables 
1-3 matched to the known functions 
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Taken together, our results show that miR-200c plays a crucial role in cancer 
progression, by modulating the protein expression leading to a change of fundamental 
physiological properties, i.e. increasing metabolism and proliferation, the induction of 
EMT and enabling cell migration as well as increasing chemoresistance (Figure 13). 
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3.4. Discussion 
Recent publications on the role of miR-200c in cancer progression and metastasis28,74 
point towards a multilayered and complex interplay92, also involving other numerous 
pathways like angiogenesis and therapy resistance72,93. These facts emphasize the 
need to utilize more comprehensive tools like genomics and proteomics, as key to 
generate novel insights. With the genomic knock-out, followed by proteome analysis, 
we chose two state-of-the-art techniques to investigate new modes of action of 
miR-200c. 
While knock-outs of protein coding genes are quite common, the genetic disruption of 
non-coding regulatory RNAs is still rarely reported. CRISPR/Cas9 is probably the most 
frequently utilized genome-editing technology at this time, nevertheless this tool’s main 
disadvantage lies in the tendency to off-target cleavage29,84. Also, the need of a 
PAM-sequence may impede certain knock-out strategies, especially when site-specific 
mutations are necessary. While different modifications were performed to enhance 
Cas9’s specificity, like the conversion to the Cas9n nickase-mutant or rational design 
of the nuclease87,94, TALENs offer high specificity from the beginning, as was also 
demonstrated by successful use in a first human patient95. Therefore, in our experiment 
we chose to utilize TALENs, allowing us to specifically target the miRNA’s drosha 
processing site30,88. The genetic disruption in the drosha site minimizes the risk of 
inducing a mutation in the seed region, which could lead to the generation of a new, 
artificial miRNA with unpredictable off-targets. Kim et al. provided the pre-designed 
TALENs-plasmids, and previously showed that a mutations of the drosha processing 
site leads to a decrease in miR-expression. Further, the group was able to verify the 
KO-strategy for miR-200c by demonstrating effects of the miR-200c KO in the 
Her2-positive SK-BR-3 cell line, like an increase of the miRNA’s seed-targets via a 
motif enrichment analysis and decreased proliferation88. 
In our work, we were able to generate mutations in both alleles of miR-200c in three 
independent clones, namely M1, M2 and M3, as well as one clone with a heterozygous 
mutation, i.e. MCtrl. As miR-200c family members share most of their sequence and 
were reported to have similar functions72,73, and as the knock-out of a gene can induce 
compensation effects96, it was necessary to analyze the expression of the family 
members after the knock-out of miR-200c. The measurements emphasize the general 
importance of miR-200c among its family members in this cell line, as the levels are 
about 20-fold higher than the average miR-200c-family members. No significant 
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transcriptional compensation of any other family member was observed. In MCtrl the 
compensation of the loss of one-allele could be based on a higher transcription rate of 
the polycistronic unit, which would result in higher levels of miR-141. However, the 
observed increase in miR-141 expression is not significantly higher and does not 
correlate with the increase needed for the compensation of the loss of one allele of 
miR-200c needed. These findings together suggest a different compensatory 
mechanism in MCtrl, like inhibited degradation or changes in the miRNA processing of 
miRNA-200c. Still, it is not clear whether the basal expression levels of miR-200b and 
miR-429, which share the same seed region as miR-200c, could suffice for the 
regulation of certain targets and pathways. 
Only few miRNA-knock-outs, especially with TALENs, were described before97 98, but 
the subsequent target analysis has been mainly based on genomic approaches. The 
protein expression profile analysis therefore may reveal important novel information 
about the regulation network of miRNA-200c. In the proteomic approach, three 
knock-out clones were analyzed and compared to both: the wild-type cells as well as 
MCtrl with a heterozygous mutation. The later was chosen, as the expression level of 
miR-200c was not significantly changed, and the clone went through the same 
procedures as the miR-200c KOs. Therefore, it served as an appropriate control, to 
rule out expression changes based solely on selection and introduction of TALENs 
proteins. 
The PCA underlines the similarity of MCtrl to the wild type, prompting us to regard both 
as control groups. Moreover, a clustering analysis shows a close correlation between 
the replicas, as well as a tendency towards grouping the KO clones close together. 
This indicates that the knock-out of miR-200c does not lead to dramatic changes in the 
proteome, but to a surgical change in key elements and pathways, which are important 
for tumorigenesis. 
For a comprehensive overview of changed expression patterns, we utilized two 
independent bioinformatic methods. While the DAVID analysis is based on p-value 
pre-filtered set of proteins, analyzing gene ontology annotations on a broad level, the 
GSEA-Tool generates results due to a list-walk enrichment scoring analysis. Both 
analyses showed similar results, while used for a different purpose. One aim was to 
investigate pathways that are attributed to miR-200c expression and are involved in 
previously described physiological processes in cancer, like change in metabolic 
processes, EMT99,100 and resistance to chemotherapeutics27. The DAVID Analysis 
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enabled a global understanding of process-changes attributed to a small set of 
differentially regulated proteins, revealing changes in metabolism and cellular 
organization in general. With the GSEA, we were able to analyze certain crucial 
pathways in cancer in detail, revealing changes in cancer progression and metastasis. 
This is shown by enrichments in pathways increasing metabolic activity, loss of cell 
cycle regulation and actin cytoskeleton as well as cell-cell contacts. These findings, 
based on changes of protein expression were successfully correlated to phenotypes 
of the cells after the KO. After eradication of miR-200c expression, the cells showed 
increased migration, which could be attributed to changes in focal adhesion and 
cellular interaction. Also, increased NADP(H) turnover, as measurement of 
proliferation and metabolic activity is observed in the KO clones, which may also 
contribute to the increased resistance to doxorubicine treatment. The latter can also 
be caused by an increase of detoxification and the evasion of apoptosis.  
While we do see changes in pathways and targets involved in cell motility and 
morphology as well as a changed phenotype towards more migratory cells, common 
EMT markers like vimentin were not found and E-cadherin expression was unchanged. 
Epithelial MCF7 cells express low levels of ZEB1/2, as was confirmed previously101. 
Our data suggests that the miR-200c KO as such does not lead to an activation of 
ZEB1/2 and eventually to a decrease of E-cadherin. This may be due to the poised 
chromatin structures102 and not due to a persistent down-regulation via miR-200c. Our 
data suggests that miR-200c has additional effects on the cytoskeletal organization 
besides the ZEB1/2 axis, as was also proposed before 103. 
In more detail, the analysis of 675 proteins showed significant differential expression 
in 21 proteins in total, nine of those to a high extend in all three biological replicas. 
None of the obtained targets shown in Tables 1-3 was published to be regulated by 
miR-200c before. Comparing a list of confirmed miR-200c targets72 to our whole 
proteomics dataset, we found only 1 of 37 to be present, i.e. PRDX2. This protein 
displayed no significant differential expression in our analysis. The lack of prominent 
miR-200c targets in our tables may be based on different cell line models, as well as 
different analytical and experimental approaches used in the studies. Our proteomic 
approach as method does not allow gathering information of the whole proteome. Still, 
in this case the analysis of protein expression compared to a transcriptomic method 
may be beneficial, due to mainly translational changes which are expected after a 
miRNA KO. Nevertheless, on the basis of our data, it cannot be excluded that certain 
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family members may facilitate the regulation of certain proteins, without changing their 
own expression. Even low expression of miRNAs may be enough to regulate 
translation, especially for low abundant proteins which often cannot be detected 
appropriately in proteomics approaches. 
The regulatory mechanisms of miR200c seems to be different in our model cell line 
MCF7. MCF7 cells show high expression of miR-200c and as miRNA-inhibition is not 
very common this cell line model is not frequently used in miR-200c research. 
Consequently, most published miR-200c targets were unraveled in other cellular 
systems. Additionally, the KO of an inhibitor leads to different results than the 
addition/overexpression of it, which was performed in the majority of the published 
studies. In a KO only physiologically direct targets and corresponding downstream 
effects become obvious while other inhibitory mechanisms (e.g. DNA methylation) are 
not affected in our settings and thus these potential miR-targets display no altered 
expression.  
Moreover, we were analyzing a KO which is a longterm effect and might display 
different changes than those observed in transient overexpression or inhibition models. 
Transient experiments additionally may lack compensatory mechanisms. 
While transient inhibition of miR-200c has revealed several functions in breast cancer, 
the long-term disruption of the gene may be more similar to the setting in a tumor. 
Of note, it was shown that miR-200c expression can be lost due to locus methylation, 
leading to more aggressive breast cancer phenotypes104. With our approach we were 
able to discover novel targets which are truly governed by miR-200c in MCF7 cells and 
might play crucial roles in normal cellular settings. 
Based on the information from the GO-Database, these targets were allocated to their 
main biological function: Most of the proteins play a role in cellular processes involving 
the cytoskeleton, metabolism and detoxification. This supports previous studies of 
miR-200c’s function in EMT, proliferation and chemoresistance27,28,99,100, while 
additionally revealing yet unknown miR-200c downstream proteins.  
Our findings were affirmed by validation of changes on mRNA level by RT-qPCR on a 
set of six novel miR-200c targets (namely FLNA, FLNB, AGR2, SCIN, GSTM3 and 
ALHD7A1), originating from different data-mining methods and pathways.  
Filamins A and B (FLNA, FLNB. Further, filamins can cause cell migration and 
invasion, by mediation of HGF/c-MET signaling as shown in hepatocytes105, as well as 
via the interplay with Cyclin D in highly metastatic human MDA-MB-231 cells106, which 
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lack the expression of miR-200c27. Notably, also in a set of miR-200c low triple negative 
breast cancers (including MDA-MB-231) it was reported that filamin A107 knock-down 
leads to increased chemosensitivity to docetaxel.  
Different proteins may contribute to enrichments in metabolic and cellular processes, 
like the Anterior Gradient Protein 2 Homolog (AGR2). AGR2 has been shown to play 
a critical role in numerous cancers and other diseases108, but especially in breast 
cancer, a high AGR2 expression shows negative effects on survival of tamoxifen 
treated patients109. After overexpression in vitro, increased proliferation and drug 
resistance to cisplatin was shown in A375 cell line110 and even a apoptotic bystander 
effect of cancer cells on normal cells was shown111. These findings suggest an 
influence of AGR2 on drug resistance and breast cancer progression and as the 
miR-200c knock-out significantly increases its expression, miR-200c may be an 
important regulatory system for AGR2 expression. GSTM3, glutathione S-transferase 
Mu3 is a member of the glutathione transferase superfamily, which are known to play 
an important role in different processes of detoxification, likely also of 
chemotherapeutic drugs112. Recent publications show that inhibiting glutathione 
transferases may overcome resistance to platin-based DNA damaging drugs113. 
Furthermore, Adseverin, the Calcium-Dependent Actin Severing and Capping Protein 
(SCIN), has been shown to have effects on different cancers. While no observations 
in breast cancer were reported, previous data show that a silencing of SCIN leads to a 
decrease in proliferation of A549 and H1299 lung carcinoma cells114. SCIN was also 
described as a driver in metastasis and outcome marker in patients with gastric 
cancer115, as well as its role in mediation of cisplatin resistance in bladder cancer 
cells116. All these findings correlate with effects observed in loss-of-miR-200c 
scenarios, which according to our data leads to an increase in SCIN. 
Aldehyde dehydrogenases are a family of proteins oxidating aldehydes to carboxylic 
acids in NADP(H) dependent manner. Due to xenobiotics, reactive oxygen species 
(ROS) accumulate, finally leading to oxidative stress. Brocker et al. suggest ALDH7A1 
may play an important role in the defense of the cell against oxidative stress and its 
cytotoxicity117. As the cytotoxic effect of doxorubicin and similar drugs is in parts 
accounted to reactive oxygen species (ROS) and oxidative stress118,119, the loss of 
miR-200c may cause the increase of ALHD7A1, leading to an increase in resistance 
to these therapeutics. 
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In this study, we combined a miRNA knock-out with a proteome analysis to investigate 
long-term effects, analogues to the loss of miR-200c during tumor progression in 
patients. Thereby, we were able to confirm known mechanisms of miR-200c, as shown 
by enrichment and pathway analysis. Moreover, we unraveled a set of novel target 
candidates involved in those mechanisms and were able to confirm the predicted 
effects by biological assays. Our data further emphasizes the role of miR-200c in 
tumorigenesis and underscores its potential as biomarker as well as putative 
therapeutic agent for miRNA-based therapies. 
3.5. Materials and methods 
Reagents 
Puromycin dihydrochloride and Doxorubicine hydrochloride were obtained from Sigma-Aldrich 
(cat. P8833, D1515).  
Cell culture 
MCF7 cells stably expressing eGFP were generated in our lab. The parental cells were 
acquired from cell line service (Eppelheim, Germany), grown at 37 °C and 5 % CO2 in 
high glucose DMEM (Sigma) supplemented with 10 % fetal calf serum (FCS / Gibco), 
as well as the miR-200c KO clones M1, M2, M3 and MCtrl. All cells were routinely 
tested and confirmed as mycoplasm free. 
 
miR-200c knock-out 
Analysis for putative CRISPR-Targets was performed via the CRISPR-Design Tool 
from Feng Zhang’s lab (http://crispr.mit.edu, last target review: 18th of January, 2017) 
120.The TALENs pair was acquired from the TALENs Library of the Seoul National 
University (http://cge.ibs.re.kr/html/cge_en/)88, the binding sequences for left and right 
TALENs are: CTAATACTGCCGGGTAATGA, TCCCTGTGTCAGCAACATCCA – 
respectively, the target sequence is TGGAGGCCCCTG. In order to develop a stable 
miR-200c KO in MCF7 cells, 600,000 cells per well were seeded in a 6 well plate and 
transfected on the following day with 3µg DNA (equimolar ratio of two TALENs and a 
reporter plasmid containing a puromycin resistance cassette and red fluorescence 
protein (RFP)) using K2 Transfection System (Biontex) according to the manufacturers 
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protocol. Two days post transfection, the cells were selected with 1 µg/ml of puromycin 
for two weeks, followed by single cell dilution to obtain monoclonal cultures. 
DNA was extracted using Phenol-Chloroform (both Sigma), and analyzed by the T7-
Surveyor assay (NEB). In mutation-positive clones, a sequencing of the miR-200c 
gene locus was performed. Three homozygous miR-200c KO clones were acquired, 
called M1, M2 and M3. The reporter-plasmid (SBI cat. MIR-KO-200cHR-1), comprises 
a puromycin and RFP reporter.  
 
Sequencing 
DNA was extracted from MCF7 miR-200c KO cells using the standard protocol 
(phenol-chloroform). Approximately 500ng of DNA were used to amplify the miR-200c 
gene using the following primers:  
Forward CTCGAGGCTCACCAGGAAGTGTCCCC 
Reverse ACGCGTCCTTGTGCAACGCTCTCAGC. 
The PCR product was purified by a PCR purification Kit (Qiagen Cat. 28104) and 
finally 50 – 100 ng of purified PCR product was sequenced (GATC Biotech AG). 
 
miRNA quantitative RT-PCR 
Approximately 600,000 cells of each clone were harvested and total RNA isolated from 
cells using miRCURY RNA Isolation Kit (Exiqon). cDNA synthesis was carried out by 
a microRNA specific reverse transcription and detection with the qScript microRNA 
cDNA Synthesis Kit and PerfeCta SYBR Green SuperMix (Quanta Biosciences) with 
RT-PCR detection on a LightCycler 480 (Roche). The expression of miR-200 family 
members (miR-141, miR-200a, miR-200b, miR-200c) was normalized to miR-191121, 
using the 2-∆CT or 2-∆∆CT method. The following list contains the primers used for 
analysis of miRNAs:  
miR200c: GCGTAATACTGCCGGGTAAT;  
miR-191: GCGCAACGGAATCCCAAAAG;  
miR-141:GCGTAACACTGTCTGGTAAAGA; 
miR-200a: GAGTAACACTGTCTGGTAACGA; 
miR-200b:GCGTAATACTGCCTGGTAATGA; 
miR-429: GAGTAATACTGTCTGGTAAAACC  
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Sample preparation for proteomic analysis 
Protein was extracted from approximately 6x106 cells using lysis buffer containing 8 M 
urea and 400 mM NH4HCO3. Briefly, cells were washed three times with cold PBS, 
treated with lysis buffer and harvested using cell scrapper. Lysates were concentrated 
with QIA-shredder mini spin column (Qiagen, Germany) following manufacturer’s 
instruction. Protein quantifications were performed using BCA Protein Assay Kit 
(Thermo Fisher Scientific). 20 µg of protein were prepared for disulfide bond reduction 
by adding 45 mM of dithioerythritol (DTE), and incubated for 30 min at room 
temperature. Alkylation of cysteines was performed by adding 0.1M iodocetamide, 
followed by 30 min incubation at room temperature in the dark. Water was added to a 
concentration of 1M urea. 400 ng sequencing grade modified porcine trypsin 
(Promega, Madison, WI, USA) was added for overnight incubation at 37 oC. 
Afterwards, samples were purified using C18 spin columns (Pierce, Thermo Scientific, 
IL, USA) complying manufacturer’s instruction. Resulting supernatants were combined 
and freeze-drying was performed. Peptide samples were stored at -20 °C prior to LC-
MS/MS.  
 
Proteomic LC-MS/MS analysis 
Samples were diluted in 0.1 % formic acid. Nano-LC separation was done with a nano-
liquid chromatography system (EASY-nLC 1000, Thermo Scientific, USA)). 2.5 µg of 
peptide samples were loaded onto a trap column (PepMap100 C18, 75 µm x 2 cm, 3 
µm particles, Thermo Scientific) and separated at a flow rate of 200 nl/min by an 
analytical reversed phase column (PepMap RSLC C18, 75 µm x 50 cm, 2 µm particles, 
Thermo Scientific) using a 260 min gradient from 5 % B to 25 % B (solvent A: 0.1 % 
formic acid; solvent B: CH3CN/0.1 % formic acid) followed by a 60 min gradient from 
25 % to 50 % B. Tandem mass spectrometry was performed with an Orbitrap XL mass 
spectrometer (Thermo Scientific, USA). MS and MS/MS spectra were acquired using 
cycles of one MS scan (mass range m/z 300-2000) and five subsequent data 
dependent CID MS/MS scans (dynamic exclusion activated; collision energy: 35%). 
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Analysis of proteomic data and bioinformatics processing 
All data were processed with MaxQuant and analyzed in Perseus  
(version 1.5.3.2)122-124 at an FDR of 1 % for the peptide and protein level. In Perseus, 
following operations were performed: Transformation (log2) and removal of possible 
contaminants and false positive identifications from the reversed database. For relative 
quantification, only those proteins were considered that showed valid LFQ-values in all 
three replicas in all samples. No imputation was performed. 
In addition, proteins were considered “ON” when at least 5 valid values were found in 
M1, M2 and M3, and no value in the control. Proteins were considered “OFF” when at 
least 3 valid values were found in MCtrl and MCF7 and not at all in the KO group. 
For pathway analysis, the whole data set was re-analyzed: After transformation and 
removal of contaminants and false positives, data was filtered for proteins found at 
least 3 times in one of the groups KO or Ctrl. The whole dataset was analyzed by the 
Gene Set Enrichment tool (GSEA, version 3.0 beta2)91, following the originators’ 
instructions. For analysis with DAVID Bioinformatics 6.790, proteins were chosen which 
showed p<0.05 in a two-tailed student’s t-test, comparing Ctrl to KO group. 
 
Analysis of miR-200c binding in genes of target proteins 
For the analysis of a potential miR-200c binding in the found genes, the Targetscan 
7.1 database125 was used. 
 
Analysis of transcription factors in promoter regions of found genes 
For the analysis of the promoter region, each gene’s sequence was retrieved from the 
RefSeq-Database (https://www.ncbi.nlm.nih.gov/refseq/ as of April 2017) in order to 
identify the +1 position. Assuming the +1 position as starting site of transcription, 500 
nucleotides upstream were defined as the proximal promoter. Then, for analysis of 
proximal promoters, PhysBinder61 software was used, the analysis was performed with 
the highest stringency. The resulting transcription factors were evaluated for miR-200c 
and family binding with Targetscan 7.1 125.  
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qPCR validation of mRNA expression 
RNA was extracted utilizing the Total RNA Kit, peqGOLD (VWR) as by manufacturer’s 
instructions. Translation to cDNA was performed utilizing the qScript cDNA synthesis 
kit (Quanta Bioscience) as by manufacturer’s protocol. 
Analysis of expression was performed with the Lightcycler 480 (Roche) and the 
Universal Probe Library (Roche) with following probe and primer (forward/reverse) 
combinations: 
AGR2, Probe 47, GGTGGGTGAGGAAATCCAG / GTAGGAGAGGGCCACAAGG 
ALDH7A1, Probe 7, CACTCAGGTGGGAAAACAGG / AATGGCATTGTTTCCTCCAA 
FLNA, Probe 32, TCGCTCTCAGGAACAGCA / TTAATTAAAGTCGCAGGCACCTA 
FLNB, Probe 21, CGGACTTCGTGGTAGAATCC / TGAGAGGGGCCTTCAATG 
GSTM3, Probe 85, CCAATGGCTGGATGTGAAAT / TCCAGGAGGTAGGGCAGAT 
SCIN, Probe 19, TTTCAAAGGCGGTCTGAAAT / CAGGTCGTTCGTAAGAACATGA 
 
Measurements of metabolic activity 
All clones were seeded triplicates in a concentration of 5000 cells / well in four identical 
96-well plates. The cells were treated with 10µl of 5 mg/ml MTT (Sigma Aldrich) at the 
timepoints 0h (about 2h after seeding) and 24h, 48h and 72h later respectively. The 
plates were incubated for 2h at 37°C and stored at -80°C over night. Afterwards100µl 
DMSO (Sigma Aldrich) were added and incubated for 37°C for 30mins, while shaking. 
Measurements were performed with the Spark 10M (TECAN). 
 
Live cell imaging and 2D migration 
Live Cell Imaging was performed using a Nikon Eclipse Ti Inverted Microscope (Nikon, 
Düsseldorf, Germany). Cells were kept under constant 37°C, 5% CO2 and 80% 
humidity by the heating and incubation system from Ibidi (Martinsried, Germany). 
Imaging was performed with the 10x phase contrast objective. For the 2D migration 
experiments 8-well slides (Ibidi, Martinsried, Germany) were coated with 50 µg/ml 
fibronectin for 1 h, afterwards cells were seeded in a density of 25x103/well, and were 
allowed to attach to the coated surface for 2 h. Cell Displacement was imaged every 
10 min over 20 h in all settings. For analysis of movement, single cells were tracked 
manually using ImageJ Manual Tracking Plugin. Acquired trajectories in 2D were 
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further analyzed for mean velocity using Ibidi Chemotaxis and migration tool, 
afterwards an outlier-analysis was performed by the Identify outliers tool of Prism 
GaphPad. 
 
Clonogenic assay 
1000 cells were seeded in a 6-well plate (TPP, Switzerland), and grown for 7 days, 
fixed and stained with paraformaldehyde (PFA) containing crystal violet (Sigma). 
Survival colony were analysed by ImageJ ColonyArea 
 
Doxorubicine resistance 
All clones were seeded in a concentration of 5000 cells per well in 96 well plates. 24h 
after seeding, cells were treated with 1 µM Doxorubicine for 48h (Sigma Aldrich, stock 
10mM in DMSO). Analysis of viability was performed via Celltiter-Glo assay (Promega) 
and normalized to DMSO control. 
 
Statistical analysis  
Results are expressed as the mean ± SD of at least three biological replicas, if not 
stated otherwise. Software GraphPad Prism v6 and SigmaPlot 11 were utilized for the 
analysis of the data. For analysis of miR-200c expression (only one variable and more 
than two groups), the One Way Analysis of Variance test was used, followed by the 
two tailed Bonferroni´s multiple comparison test, with DF = 4. For analysis of all family 
members (two variables and more than two groups per variable), the Two Way 
Analysis of Variance test was used, followed by two tailed Bonferroni´s multiple 
comparison test with DF = 16. For analysis of family expression between early and late 
passage (three variables and more than two groups per variable) we used the Three 
Way Analysis of Variance test, followed by two tailed Bonferroni´s multiple comparison 
test, with DF = 12  
 
Data availability 
The data that support the findings of this study are available from the corresponding 
author upon reasonable request.  
3. A proteomic analysis of an in vitro knock-out of miRNA-200c  
Dissertation - Bojan Ljepoja | 54 |  
3.6. Supplemental information 
 
Supplement S 1 
Clustering analysis of the measurements after vertical and horizontal z-score normalization 
Supplement S 2 
Venn-diagramm with results of the vulcano blot analysis of M1 or M2 or M3 vs (MCF7 and MCtrl) each 
N=675 with 250 randomizations, FDR 0.05 and S0 of 0.1 as shown in Table 2 
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Supplement S 3 
Detailed results of  
Figure 10F, with mRNA measurements compared to the protein expression data for each clone 
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Supplement S 4 
Heatmaps corresponding to the Enrichment blots in Figure 11c 
 
 
Supplement S 5 
Heatmaps corresponding to the Enrichment blots in Figure 11d  
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Supplement S 6 
Evaluation of migration data in Figure 12b (N=30, *p<0.05, one-way ANOVA with post-hoc Bonferroni’s 
multiple comparison) 
 
 
Supplement S 7 
Clonogenic assay – imaging of colonies, as evaluated in the pooled analysis in Figure 12d 
Supplement S 8 
qPCR measurements of E-Cadherin mRNA levels in Ctrl vs KOs shows no significant difference 
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Supplemental Table S 1 15 / 32 gene sets are enriched in phenotype KO 
NAME SIZE ES NES NOM p-val FDR q-val FWER p-val RANK AT MAX LEADING EDGE 
KEGG_PARKINSONS_DISEASE 34 0.46907002 15.940.783 0.009861933 0.24380365 0.214 345 tags=50%, list=28%, signal=67% 
KEGG_OXIDATIVE_PHOSPHORYLATION 33 0.48710477 15.471.032 0.018480493 0.17806831 0.293 345 tags=52%, list=28%, signal=70% 
KEGG_ALZHEIMERS_DISEASE 35 0.420356 14.566.842 0.046 0.24040706 0.479 292 tags=40%, list=24%, signal=51% 
KEGG_CITRATE_CYCLE_TCA_CYCLE 20 0.4615872 13.821.458 0.12048193 0.29699662 0.648 132 tags=30%, list=11%, signal=33% 
KEGG_HUNTINGTONS_DISEASE 43 0.36943752 13.720.317 0.03508772 0.2523027 0.664 292 tags=42%, list=24%, signal=53% 
KEGG_GLUTATHIONE_METABOLISM 15 0.44105875 13.544.401 0.08317215 0.23395455 0.703 78 tags=27%, list=6%, signal=28% 
KEGG_MAPK_SIGNALING_PATHWAY 16 0.4151188 13.413.316 0.10453649 0.22068681 0.734 136 tags=25%, list=11%, signal=28% 
KEGG_AMINOACYL_TRNA_BIOSYNTHESIS 20 0.44356683 13.299.485 0.15369262 0.20533033 0.744 263 tags=40%, list=21%, signal=50% 
KEGG_CARDIAC_MUSCLE_CONTRACTION 17 0.46564567 12.798.785 0.18257262 0.23733874 0.82 292 tags=53%, list=24%, signal=68% 
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 15 0.42715377 12.191.079 0.24395162 0.285524 0.892 308 tags=47%, list=25%, signal=61% 
KEGG_PYRUVATE_METABOLISM 15 0.49441242 11.757.169 0.28846154 0.31522772 0.919 122 tags=33%, list=10%, signal=37% 
KEGG_GLYCOLYSIS_GLUCONEOGENESIS 23 0.39739954 11.214.875 0.33840305 0.35995352 0.95 200 tags=30%, list=16%, signal=36% 
KEGG_FOCAL_ADHESION 24 0.30988422 10.625.255 0.36055776 0.41783723 0.972 277 tags=29%, list=22%, signal=37% 
KEGG_LYSOSOME 17 0.24309203 0.69935 0.9089184 0.94843 1.0 162 tags=18%, list=13%, signal=20% 
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION 17 0.19984435 0.660395 0.934236 0.92140806 1.0 195 tags=18%, list=16%, signal=21% 
 
Supplemental Table S 2 17 / 32 gene sets are upregulated in phenotype 
NAME SIZE ES NES NOM p-val FDR q-val FWER p-val RANK AT MAX LEADING EDGE 
KEGG_CELL_CYCLE 22 -0.51119137 -16.219.078 0.035643563 0.19916053 0.172 348 tags=55%, list=28%, signal=75% 
KEGG_RIBOSOME 68 -0.31785846 -14.187.368 0.016746411 0.49701187 0.529 392 tags=41%, list=32%, signal=57% 
KEGG_ENDOCYTOSIS 20 -0.40655762 -13.007.351 0.12331407 0.70801485 0.78 193 tags=30%, list=16%, signal=35% 
KEGG_PURINE_METABOLISM 23 -0.36597934 -11.775.029 0.24390244 0.9449636 0.925 14 tags=13%, list=1%, signal=13% 
KEGG_PROTEASOME 34 -0.30099234 -11.316.409 0.29045644 0.9364207 0.95 457 tags=53%, list=37%, signal=82% 
KEGG_ADHERENS_JUNCTION 15 -0.35883263 -11.289.837 0.28879312 0.78668696 0.95 338 tags=53%, list=27%, signal=73% 
KEGG_TIGHT_JUNCTION 20 -0.3472254 -10.904.311 0.3391473 0.7903667 0.964 294 tags=40%, list=24%, signal=52% 
KEGG_OOCYTE_MEIOSIS 19 -0.3068673 -0.99786586 0.49278352 0.9669546 0.988 440 tags=58%, list=36%, signal=89% 
KEGG_UBIQUITIN_MEDIATED_PROTEOLYSIS 16 -0.319742 -0.979242 0.4989059 0.909404 0.991 251 tags=31%, list=20%, signal=39% 
KEGG_INSULIN_SIGNALING_PATHWAY 17 -0.29883376 -0.95862424 0.51827955 0.8756116 0.994 256 tags=35%, list=21%, signal=44% 
KEGG_REGULATION_OF_ACTIN_CYTOSKELETON 36 -0.24238425 -0.9287425 0.6079295 0.8686062 0.998 275 tags=31%, list=22%, signal=38% 
KEGG_PATHOGENIC_ESCHERICHIA_COLI_INFECTION 22 -0.28710213 -0.9233835 0.595092 0.8081302 0.998 514 tags=55%, list=42%, signal=92% 
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY 17 -0.29578927 -0.90542006 0.5875831 0.7824528 0.999 440 tags=59%, list=36%, signal=90% 
KEGG_SPLICEOSOME 58 -0.22438549 -0.8703807 0.6956522 0.7967216 0.999 364 tags=38%, list=29%, signal=51% 
KEGG_PATHWAYS_IN_CANCER 27 -0.22919808 -0.7894147 0.8729839 0.8798361 0.999 338 tags=41%, list=27%, signal=55% 
KEGG_FC_GAMMA_R_MEDIATED_PHAGOCYTOSIS 16 -0.24920684 -0.7617598 0.872 0.8646141 1.0 218 tags=25%, list=18%, signal=30% 
KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 16 -0.28722718 -0.7255098 0.8017058 0.8583328 1.0 362 tags=44%, list=29%, signal=61% 
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Supplemental Table S 3 Overview of predicted transcription-factor binding sites 
 
 
Dissertation - Bojan Ljepoja | 60 |  
4. Inducible miRNA-200c decreases motility of breast cancer cells 
and reduces filamin A 
The following sections are directly adapted from the original manuscript. 
 
Inducible microRNA-200c decreases motility of breast cancer cells and 
reduces filamin A 
Bojan Ljepoja1, Christoph Schreiber2, Florian A. Gegenfurtner3, Jonathan García-
Roman1, Stefan Zahler3, Joachim O. Rädler2, Ernst Wagner1, Andreas Roidl1* 
In Submission 
 
1Pharmaceutical Biotechnology, Department of Pharmacy, Ludwig-Maximilians-
Universität München, Munich, Germany 
2Faculty of Physics and Center for NanoScience, Ludwig-Maximilians-Universität 
München, Munich, Germany 
3Pharmaceutical Biology, Department of Pharmacy, Ludwig-Maximilians-Universität 
München, Munich, Germany 
 
Contributions: 
BL performed the experiments and wrote the paper. CS performed the 1D migration 
assays and wrote the paper. FAG performed the imaging experiments and wrote the 
paper. JGR generated the TRIPZ-constructs and performed the transcription factor 
analysis. SZ, JOR and EW provided conceptual advice. AR conceived the study and 
wrote the manuscript. All authors commented on the manuscript and conclusions of 
this work. 
 
  
4. Inducible miR-200c decreases motility of breast cancer cells and reduces filamin A  
Dissertation - Bojan Ljepoja | 61 |  
4.1. Abstract 
Cancer progression and metastases are frequently related to changes of cell motility. 
Amongst others, the microRNA-200c (miR-200c) was shown to maintain the epithelial 
state of cells and to hamper migration. Here, we describe two miR-200c inducible 
breast cancer cell lines, derived from miR-200c knock-out MCF7 cells as well as from 
the miR-200c-negative MDA-MB-231 cells and report on the emerging phenotypic 
effects after miR-200s induction. miRNA-200c expression appears to cause. The 
induction of miR-200c expression seems to effect a rapid reduction of cell motility, as 
determined by 1D microlane migration assays. Sustained expression of miR200c leads 
to a changed morphology and reveals a novel mechanism by which miR-200c 
interferes with cytoskeletal components. We find that filamin A expression is 
attenuated by miRNA-200c induced downregulation of the transcription factors c-Jun 
and MRTF/SRF.This potentially novel pathway that is independent of the prominent 
ZEB axis could lead to a broader understanding of the role that miR200c plays in 
cancer metastasis.  
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4.2. Introduction 
Metastasis, i.e. the nesting of tumor cells in adjacent tissues and even distant organs, 
is one of the most malicious aspects of cancer, causing nine out of ten cancer  
deaths 126. While primary tumors often can be treated well, the uncontrollable spread 
of cancer cells remains a major challenge in most clinical settings. One prevalent 
example for risks of metastatic cancers are tumors of the breast, which show a clear 
association between metastasis and survival of patients 127,128. While the primary 
breast carcinomas show rather good resectability due to their location, the cancer often 
has reached distant organs before the primary tumor was detected. Progress in 
understanding the disease has been made by identifying certain subtypes of breast 
tumor cells which inherit particularly high metastatic potentials 129. However, current 
studies show a rise in incidence of metastatic breast cancer 130. Therefore, still more 
and deeper insights into the key regulators of migratory and metastatic processes are 
needed. 
Epithelial to mesenchymal transition (EMT) is often regarded as one of the most 
important steps in the initiation of migration and thus the onset of invasion and 
metastasis of tumors 131-133. While EMT can be influenced by multiple cellular 
processes, RNA interference by microRNAs (miRNAs) was shown to be a direct and 
important regulatory mechanism 63.  
In general, miRNAs are small, non-coding RNAs, influencing the translation of multiple 
fundamental cellular processes like metabolism, proliferation and cellular organization. 
Even small changes in miRNA expression patterns can have tremendous impact on 
the cell fate and can prompt towards various malignancies or even be the root cause 
of those 65,69,70. One miRNA family with important implications in cancer is the miR-200 
family, consisting of miR-200a, miR-200b, miR-141, miR-429 and miR-200c. While all 
members have demonstrated effects in the regulation of cancer processes, miR-200c 
is the family member which unifies well investigated associations in the most important 
cancer pathways, like the inhibition of chemoresistance27,134,135, regulation of metabolic 
activity28,67,72 and also in epithelial-to-mesenchymal transition (EMT) and thus 
potentially cancer cell metastasis 26,27,72,74,92,99.  
MiR-200c’s role in the regulation of EMT is based on its stabilizing effect on the 
expression of E-cadherin by preventing the inhibition of E-cadherin by ZEB1 and ZEB2 
(Zinc finger E-box-binding homeobox members1 and 2). Previous studies have shown 
that the introduction or re-expression of miR-200c in vitro reverses the mesenchymal 
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phenotype of cancer cells, i.e. leading to EMT reversion, termed MET (mesenchymal 
to epithelial transition) 74,99.  
Although EMT may be one of the main pathways of metastasis induced by the loss of 
miR-200c, the metastatic capabilities of tumor cells also rely on multiple other 
mechanisms. Interestingly, miR-200c was shown to influence other migratory 
pathways, for example by regulation of fibronectin secretion and moesin expression or 
by targeting the SRF-regulating proteins FHOD1 and PPM1F 26,100,103.  
To further investigate the function of miR-200c as regulator of both, ZEB-dependent 
as well as independent mechanisms, we generated a genomic knock-out (KO) of 
miR-200c in MCF7 breast cancer cells in our previous work 136. The resulting KO 
phenotype showed increased migration, even of the epithelial and usually 
low-migrating MCF7 cells. A pooled proteomic analysis revealed a number of common 
differentially regulated proteins, half of which are attributed to the regulation of 
migratory processes. From this set of proteins, novel players were chosen for further 
investigation. One protein of particular interest was Filamin A, a member of the filamins 
protein family that are known building blocks of the cytoskeleton and involved in many 
cellular and migratory processes 137. Filamins, and especially filamin A, function as 
important actin filament crosslinkers, thereby facilitating actin-actin interactions, but 
also actin-connections to membrane bound proteins and intracellular signaling 
macromolecules 137,138 and previous studies described the role of filamin A in the 
regulation of cell migration 139. However, a systematic study of miRNA-200 mediated 
expression of filamin A and concomitant changes in migration has not yet been carried 
out. 
In this study, we generated two different inducible miR-200c breast cancer cell line 
models, derived from mesenchymal MDA-MB-231 cells or the miR-200c knock-out of 
the epithelial MCF7 cells, respectively. By doxycycline induction, we investigated the 
effect of increased miR-200c expression on morphological changes and motility. We 
used a micro-pattern based 1D migration assay, as described previously by Schreiber 
et al. 140 to get a multiparameter quantification of cell motility. We also found strong 
indications of a regulatory network of miR-200c and FLNA in both breast carcinoma 
models. This pathway, which is independent of the ZEB-expression of the cells, may 
point towards an important further function of miR-200c in impeding cancer metastasis. 
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4.3. Results 
4.3.1. The migratory potential of MDA-MB-231 cells decreases after 
miRNA-200c induction 
To investigate the effect of miRNA-200c induction on the metastatic potential of cells, 
we performed an in-depth analysis of single cell migration.  
Therefore, the miR-200c non-expressing, highly migratory MDA-MB-231 cell line28 was 
chosen for stable transduction with a TET-off construct containing either miR-200c or 
a scrambled control, resulting in the MDA-MB-231 TRIPZ-200c or MDA-MB-231 
TRIPZ-Ctrl cells. Treatment with doxycycline for 48 h showed a reliable and easy 
controllable induction of miR-200c expression as well as of an RFP reporter tag  
(Figure 14a, b). 
 
Figure 14 Inducible miR-200c construct with RFP reporter  
(a) Description of the inducible pTRIPZ-200c construct (b) and verification of functional transduction in 
MDA-MB-231 cells by induction of the RFP reporter tag by 5 µg / ml doxycycline for 48 h. (c) Expression 
analysis by RT-qPCR of miRNA-200c after induction with 5µg / ml doxycycline after 48 h. 
 
Using these cell lines we perform an multi-parameter analysis of motility by studying 
1D migration on ring-shaped micro-lanes. Compared to other common migratory 
assays, the real time tracking of the 1D migration allows to analyze high numbers of 
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cells and to assess a migratory fingerprint, i.e. cell velocity, cell persistence, cell resting 
times, cell run times and the run fraction, at the single cell and population level. 
For this purpose, cells were seeded on arrays of fibronectin-coated ring micropatterns 
and were observed using time-lapse microscopy (Figure 15 a, b). We found that the 
1D cell motion is divided into distinct run states, where cells move persistently in one 
direction, and rest states with no or random wiggling motion140 (Figure 15c). This two 
state analysis results in characteristic parameters quantifying cell motility (Figure 2d). 
By discriminating between run and rest states we make sure that the velocity is only 
evaluated when cells are actually migrating (𝑣run). Furthermore, we analyze the typical 
lifetime of run and rest states 𝜏run and 𝜏rest, which are exponentially distributed. This 
allows distinguishing between the stability of the run state, given by 𝜏run and the ability 
of cells to establish polarization indicated by 𝜏rest. For a comprehensive overview of 
the different motility parameters, spider-plots were generated (Figure 15e, f). As 
expected, the doxycycline induction in the MDA MB-231 TRIPZ-Ctrl cells showed no 
significant effects compared to the uninduced cells, while miR-200c induction distinctly 
changed the migratory behavior of the cells. The run velocity and the typical duration 
of a run state were significantly decreased whereas the typical duration of a rest state 
was increasing. The strongest effect was observable in the fraction of time that cells 
spent in the run state, 𝑃run, which decreased by a factor of three. Thus, induction of 
miR-200c expression affects the polarization of cells leading to longer rest states and 
a decreased persistence of the run states. To show that the decrease of persistence 
of the cell motion was also visible without the division into run and rest states we 
evaluated the persistence path q, which is given by the effective maximum 
displacement of a cell divided by the actual length of the trajectory, as described in 
Maiuri et al. 141. The described effects are visualized in a sample of a Ctrl vs a miR-200c 
induced cell, as shown in the supplemental movie 1 (SM1). On single cell level, a broad 
distribution of run velocities and a huge variance in the fraction of time spent in the run 
state was observed (Figure 15g). With increasing miR-200c expression, the distribution 
narrowed, and the average velocity was decreasing as well as the time cells spent in 
run states. Furthermore, the fraction of cells that remained in the rest states for the 
time of the whole experiment increased by almost a factor of three.  
Taken together, our data show that the induced miR-200c expression resulted in a 
reduced motility in all five migratory parameters and, hence, an overall decreased 
migratory potential. The observed process must be independent of the well 
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investigated miR-200c and ZEB1/2 induced EMT mechanisms 99; due to the fact that 
MDA-MB-231 cells are not expressing E-cadherin 101,142,143.Our findings therefore 
suggest a novel mode of miR-200c acting on migration. 
 
 
Figure 15 - miR-200c induction decreases migration of MDA-MB-231 cells as shown in the 1D 
migration assay (description next page) 
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(a) Phase contrast images of a MDA-MB 231 cell migrating on a ring shaped micro-lane. The ring is 
coated with fibronectin (edges marked in white) the surrounding is passivated with PEG. The scale bar 
is 20 µm. (b) Array of ring shaped micro lanes. Only rings that are occupied by one single cell are 
evaluated. (ring diameter 150 µm) (c) Angular position of one exemplary cell over time with classification 
into run and rest states. (d) Drawing of a cell track. Cell motion can be separated in run states with 
ballistic motion and rest states with random motion. The characteristic duration of run and rest states 
τ_run  ,τ_rest as well as the velocity in the run state v_run are evaluated. (e, f) Multi-parameter analysis 
of cell motility of cell populations. Motility of cells is measured 48h after induction with 5 µg / ml 
doxycycline (red). For MDA-MB-231 TRPZ-200c cells (f) a clear reduction of cell motility can be seen in 
all of the 5 parameters compared to no induction (grey). For MDA-MB-231 TRPZ-Ctrl cells (h) no big 
effects on motility are observed with adding doxycycline. N is the number of cells analyzed. (g) Single 
cell analysis of P_run  and v_run for the data shown in e, f) where each dot represents a single cell. One 
cell population is spread over a large range of velocities and fraction of time in the run state. Induction 
of miR 200c is causing a shift to slower velocities and less time spent in the rest state. (error bars in g 
and h indicate standard errors exept for τ_run  ,τ_rest where it’s CI of 99% of the fit)  
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4.3.2. MiRNA-200c induction changes the 3D morphology  
As a decrease in migration often correlates with changes of the cytoskeleton, we 
investigated how miR-200c affects the cellular morphology. Hence, 
immunofluorescence imaging and analysis of the cellular shape was performed. Figure 
16a shows a comparison of the actin-structure of MDA-MB-231 with either the Ctrl or 
the miR-200c construct stimulated with doxycycline for 72 h. While the TRIPZ-Ctrl cells 
maintained their mesenchymal, spindle-like shape, the miR-200c induction changed 
the cellular profile towards rounder, uniformly dilated cells as seen in the significant 
difference of the ratio of widest vs. longest spread of the cell. The three-dimensional 
shape of the cells was investigated by taking z stacks of confocal images of actin and 
filamin. Figure 16b and c show the 3D images with color coding for hight. In line with 
the previous results, the TRIPZ-Ctrl cells retained their spindle-like structure, after 72h 
and 168h of doxycycline stimulation. The miR-200c induction caused a gradual 
transition towards rounder and morphologically flatter cells over time, eventually 
resulting in evenly flat “pancake” like shape. For better visualization, these effects are 
presented in a 3D rendering animation of the stacks, shown in the supplemental 
movies (SM2 Ctrl and SM3 miR-200c). These results together show a strong effect of 
miR-200c induction on the cellular shape. 
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Figure 16 - Overexpression of miR-200c induced fast morphological changes in MDA-MB-231 
cells 
(a) Fluorescence staining of the cytoskeleton by Phalloidin (red) and nuclei (blue) in MDA-MB-231 
decreased spindle-like phenotype after induction miR-200c, as shown by significant changes in the 
shape factors (N= 30; error bars are SD; *** p > 0.001). (b,c) Renderings of stacked immunofluorescence 
images of MDA-MB-231 showed decreased mesenchymal shape in 3D after induction of miR-200c for 
(b) 72 h as well as (c) further increased effects after 168 h compared to included controls. (d) Distribution 
of filamin A in a central cross section after induction with miR-200c for 72 h and 168 h as compared to 
induced control  
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4.3.3. Changed expression of FLNA is observed after a miRNA-200c knock-
out and overexpression 
A proteomic analysis of a genomic knock out (KO) of miR-200c in MCF7 breast cancer 
cells was previously reported by our group 136. There, we showed that more than 50% 
of all differentially expressed proteins were affiliated to migratory processes (Figure 
17a). Out of these proteins, filamin A was one of the prominent and promising targets 
and therefore chosen for further analysis in this study. To study the biological effect of 
miR-200c on FLNA the inducible MDA-MB-231 TRIPZ-200c or TRIPZ-Ctrl cells were 
utilized. In line with studies of the MCF7-200c-KO cells the inverse effects regarding 
filamin A expression were observed after induction of miR-200c. Here, the mRNA 
levels of FLNA decreased to 30% and protein expression to 40% compared to 
doxycycline stimulated TRIPZ-Ctrl cells (Figure 17b, c). Additionally, an 
immunofluorescence staining of filamin A was performed in both cell line models. i.e 
the MCF7-200c-KO and the MDA-MB-231 TRIPZ-200c. The KO of miR-200c in MCF7 
resulted in increased cellular expression of filamin A (Figure 17d), while induction of 
miR-200c in MDA-MB-231 TRIPZ-200c cells resulted in decreased filamin A protein 
expression (Figure 17e). Taken together, miR-200c expression showed an indirect 
proportional relation to filamin A protein as well as mRNA in two complementary breast 
cancer cell line models.  
 
 
Figure 17 miR-200c regulates migration associated genes such as filamin A (next page) 
(a) A proteomic analysis of a TALENs knock-out (KO) of miR-200c in MCF7 cells revealed a set of 
proteins with differential expression, of which 50% are involved in migratory processes and are shown 
in the table. (RT qPCR showed that after adding 5 µg / ml doxycycline for 48 h the expression of FLNA 
mRNA (b) as well as filamin A protein(c)(normalized to tubulin) decreased significantly in MDA-MB 231 
TRIPZ 200c cells. (d) Immunofluorescence staining of filamin A (green) and DAPI (blue) in MCF7 Ctrl 
and KO 200c showed significantly increased relative intensity of filamin A, in contrast to (e) the MDA-
MB-231 cells which showed a strong decrease in filamin A intensity after induction of miR-200c (all N=3; 
error bars indicate standard deviation SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p > 0.0001)  
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4.3.4. MiRNA-200c is regulating FLNA expression via JUN and MRTF-SRF 
To further investigate the mechanism of miR-200c dependent regulation of FLNA, a 
rescue of miR-200c expression in the MCF7-200c-KO cells was performed, by stably 
introducing the inducible TRIPZ-200c plasmid. As expected, the induction successfully 
re-expressed miR-200c and consequently decreased FLNA mRNA (Figure 18a, b). 
As no miR-200c binding site was predicted in silico in the FLNA 3’UTR, other regulatory 
mechanisms were investigated. First, a promotor analysis was performed, in order to 
determine transcription factors (TFs) which are potentially regulating FLNA expression 
and contain an in silico predicted miR-200c binding-site (Figure 18c). Four of those 
TFs were identified by RT-qPCR screening after miR-200c induction in MDA-MB-231 
cells (Supplement S 9), but a reproducible decrease in expression of these TF was 
solely detected for JUN (Figure 18d). This result was confirmed in the miR-200c 
inducible MCF7 KO cells (Figure 18e).  
To investigate the effect of JUN on FLNA expression, a siRNA knockdown of JUN was 
performed in wild type MDA-MB-231 as well as in MCF7 cells and compared to 
scrambled control siRNA. In both cases, the reduction of JUN mRNA also decreased 
FLNA mRNA expression (Figure 18f, g), with stronger relative effects in MCF7 cells 
than in MDA-MB-231. 
Thus, we suggest JUN as a direct target of miR-200c and as putative regulator of FLNA 
expression. 
Another possibility of miR-200c regulating FLNA is via SRF and MRTF. It was shown 
previously that miR-200c regulates SRF and MRTF103, and also a regulation of FLNA 
by SRF was predicted in previous studies 144. Thus, we tested the hypothesis that miR-
200c is able to regulate FLNA via the MRTF/SRF axis by transiently introducing 
pgl4.34, a luciferase reporter for MRTF-dependent SRF activation, into both miR-200c 
inducible cellular systems. Here, a decrease in luciferase signal upon miR-200c 
expression was observed in both, MDA-MB-231 and MCF7 cells, compared to their 
respective doxycycline treated controls (Figure 18h, i). These results suggest a 
regulatory relation between miR-200c and FLNA based on the two different 
mechanisms, i.e. via transcriptional repression of filamin A through reduced JUN and 
the regulation by MRTF/SRF (Figure 18j). 
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Figure 18 - Filamin A is regulated by miR-200c by repression of JUN as well as SRF-MRTF (next 
page) 
(a) After introduction of the TRIPZ-200c construct into MCF7 200c KO cells, miR-200c was re-expressed 
by 48 h of DOX induction and showed (b) significantly decreased FLNA expression. (c) In silico analysis 
of the FLNA promotor revealed 6 transcription factors which have a potential miR-200c binding site. (d) 
The expression of JUN was significantly decreased 48 h after induction of miR-200c in MDA-MB-231 as 
well as (e) re-expression in MCF7 compared to the respective TRIPZ-Ctrl cell line. (f, g) Decreased 
expression of FLNA was verified in MDA-MB-231 and MCF7 after transient transfection with siRNA 
against JUN (siJUN), compared to scrambled siRNA control  (h, i) Induction of miR-200c for 48 h 
decreased the luciferase signal of a MRT-SRF reporter construct in MDA-MB-231 TRIPZ-200c as well 
as MCF7 TRIPZ-200c compared to their respective TRIPZ-Ctrl. (j) An alternative mechanism of miR-
200c regulation of FLNA is based on reducing the MRT dependent SRF activation as well as the 
transcription factor jun. (all N=3; error bars are SD; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p > 0.0001) 
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4.4. Discussion 
miR-200c is a well-established player in different types of cancer, often described as 
guardian over multiple cancer promoting pathways like metabolic activity and 
proliferation28,67,72, resistance to chemotherapeutics 27,134,135 , and inhibition of 
migration and EMT 26,72,74,92,99.  
In different clinical studies the miR-200c expression correlated with decreasing spread 
of tumors and better treatability of some cancers, as shown in different studies for 
patients with breast cancer26,77,82. In the current literature, miR-200c’s effect on 
metastasis is mainly attributed to the process of EMT, based on preventing ZEB1/2 
mediated inhibition of E-cadherin expression and thereby inhibiting the transition of 
epithelial cells to the mesenchymal phenotype74,99,104. Still, miRNA-200c has shown 
effects on migration of cell lines, which do not express the genetic axis of 
ZEB-mediated E-cadherin regulation. One issue in the investigation of additional 
migratory effects of miR-200c lies in distinguishing novel functions from effects based 
on the prominent ZEB/E-cadherin axis. Therefore, our approach has based on the 
utilization of two different breast cancer cell lines (MCF7 and MDA-MB-231) which, due 
to epigenetic predispositions101,142,143, ensure absence of ZEB/E-cadherin based 
effects. Proteomic analysis of a genomic miR-200c KO in MCF7, a high miR-200c 
expressing epithelial cell line28 emphasized the importance of miR-200c in migratory 
processes 136. 
In this study, we show the influence of miR-200c on migration based on two “gain of 
function” cell line models. First, mesenchymal and migratory MDA-MB-231 cells, which 
lack expression of miR-200c as well as E-cadherin, were transduced with a doxycycline 
inducible miR-200c expression construct (TRIPZ-200c). This approach ensured to 
minimize negative effects of transfections on the one hand, and on the other hand 
allowed for the efficient expression of miR-200c on a long-term scale, rendering the 
observation of slower processes in cellular remodeling possible. Furthermore, with the 
same construct, an inducible rescue of the miR-200c expression was performed in the 
MCF7 miR-200c KO cells. 
The induction of miR-200c caused evident changes in the morphology of MDA-MB-231 
cells, resulting in extensive remodeling of the cellular architecture as observed already 
after three days and even further increased after seven days. The resulting flat 
“pancake” shaped cells appeared to have highly decreased cellular stiffness as well as 
a lack of distinctive polarization that is commonly seen in spindle-like cells. Similar 
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observations of morphological or “spreading defects” were reported after a FLNA 
knock-down and were attributed to a deficiency in actin-crosslinking 139,145. 
In contrast to the rather slow full EMT, the effects on speed and run-times of the cells 
were observed already 48 h hours after miR-200c induction, indicating a direct 
connection of this axis to the cellular motility. The long-term stimulation showed a 
change in modality which may be similar to EMT, but a complete transition to an 
epithelial “cobblestone” phenotype was not observed, possibly due to the lack of 
development of cellular adhesions by E-cadherin. 
Furthermore, the 1D migration assay revealed decreased motility after miR-200c 
expression by showing changes of all measured parameters the decreased migratory 
capabilities of miR-200c high expressing cells show to be not based mainly on the 
absolute velocity, but more on the cells’ inability of polarizing and retaining polarization, 
as seen by the higher number of cells in temporary rest states or being completely 
immobile. 
Our previously published proteomic analysis of a genomic miR-200c KO in MCF7 
disclosed multiple changes in the expression of regulators of migratory processes, of 
which the effect on filamins A was most prominent 136. Filamin A is supposed to affect 
cell motility based on multiple pathways, like the induction of changes in the structure 
and stiffness of the cell as direct building block in the system145 or shifts in intracellular 
signaling146 and resulting in alteration of different mechanisms important for migration, 
like the actin-treadmill and formation of focal adhesions147,148 38. This important role of 
filamin A as a capable regulator of cellular migration makes it interesting to investigate 
how miR-200c regulates filamin A. Especially as we found that induced miR-200c 
expression resulted in decreased expression of FLNA in both cell systems. 
The investigation of the underlying mechanism of FLNA suppression was performed 
with two in silico analyses: The first was not yielding any predicted binding site of 
miR-200c in the FLNA 3’ UTR, while the other resulted in six potential miR-200c 
controlled transcription factors. Of the transcription factors, only JUN showed constant 
repression to miR-200c expression, which is in line with previous studies that identified 
JUN as potential miR-200c target 149. JUN expression is necessary for the formation 
of the AP-1 complex together with c-Fos. Previously, the AP-1 complex was shown to 
promote tumorigenesis, cancer progression and also regulating cell morphology and 
migration 150-152. Our experiments verified JUN promoting FLNA transcription as well 
as inhibition of JUN by miR-200c’s, resulting in decreased FLNA expression.  
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A recent study by Jurmeister et al. indicated one further possible regulatory 
mechanism. They found that miR-200c was inhibiting the MRTF dependent activation 
of SRF103. SRF is a known transcription factor of multiple immediate early genes, 
including c-fos153, and therefore an important regulator of cell growth, differentiation 
and also migration154,155 FLNA was previously144 identified as a target of SRF. 
Consistently a decreased MRTF-dependent SRF activation was observed after 
miR-200c induction, indicating an additional axis of miR-200c based regulation of 
FLNA expression. Furthermore, increased c-Fos expression due to SRF stimulation 
may also promote the additionally observed JUN-based axis, by providing additional 
partners for the assembly of the AP-1 complex. Further, FLNA was shown to promote 
the activity of SRF 156 which may further increase the investigated effects due to this 
positive feedback loop. 
Our data reveal a potential novel route of miR-200c regulating migration, independent 
of ZEB1/2. The inhibition of cytoskeletal components via miR-200c, like filamin A as 
shown here, support the role of miR-200c in maintaining the epithelial state and 
inhibiting metastasis as possibly important in a wider variety of cancer cells. 
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4.5. Materials and methods 
Puromycin dihydrochloride and doxorubicin hydrochloride were obtained from Sigma 
(cat. P8833, D1515).  
 
The MCF7 miR-200c KO cells were grown at 37 °C and 5 % CO2 in high glucose DMEM 
(Sigma) supplemented with 10 % fetal calf serum (FCS / Gibco). MDA-MB-231 cells 
were cultured at 37 °C and 0 % CO2 in L15 (Sigma) containing supplemented with 10 
% fetal calf serum (FCS / Gibco). All derived cells, i.e. MDA-MB-231 TRIPZ200c and 
Ctrl, as well as MDA-MB-231 GFP were cultured same as the parental cells. All cells 
were routinely tested and confirmed as mycoplasm free. 
The miR-200c KO via TALENs was performed as described previously136. 
 
As backbone for the TRIPZ-200c construct, the TRIPZ lentiviral inducible shRNA 
control plasmid (TRIPZ-Ctrl, Thermo Fisher Scientific, #RHS4743) was used. MiR-
200c plus 125 bp upstream and downstream flanking genomic sequences, including 
XhoI and MluI restriction sites was amplified by PCR with the following primers:  
Fwd: CTCGAGGCTCACCAGGAAGTGTCCCC  
Rev: ACGCGTCCTTGTGCAACGCTCTCAGC.  
After the construct was verified by sequencing (GATC Biotech AG), MDA-MB-231 and 
MCF7 200c KO cells were transducted with the TRIPZ-200c and TRIPZ-Ctrl utilizing a 
2nd generation lentiviral system generated with the plasmids pCMV-dR8.2 dvpr and 
pCMV-VSV-G, which were a gift from Bob Weinberg (Addgene plasmid # 8454 and 
#8455). After transduction and 48 h selection with 5 µg/ml puromycin, a single cell 
dilution was performed to generate the monoclonal TRIPZ cell lines MDA-MB-231 
TRIPZ-Ctrl, MDA-MB-231 TRIPZ-200c and MCF7 200c KO TRIPZ-200c. 
Stimulation of the cells with doxycycline was performed in a concentration of 5 µg/ml 
in the respective medium for 48 h for mRNA analysis or 72 h for protein analysis. 
Medium was replaced with fresh, doxycycline containing medium every 48h to 
compensate for doxycycline degradation. 
qPCR of miRNA was performed as described previously136, in short: 600,000 cells 
were harvested and total RNA isolated from cells using miRCURY RNA Isolation Kit 
(Exiqon). cDNA synthesis was carried out by a miRNA specific reverse transcription 
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and detection with the qScript microRNA cDNA Synthesis Kit and PerfeCta SYBR 
Green SuperMix (Quanta Biosciences) with RT-PCR detection on a LightCycler 480 
(Roche). The expression of miR-200c was normalized to miR-191121, using the 2-∆CT 
or 2-∆∆CT method.  
The following list contains the primers used for analysis of miRNAs:  
miR200c: GCGTAATACTGCCGGGTAAT; miR-191: GCGCAACGGAATCCCAAAAG;  
 
Cells were cultured in a 6 well plate for 72h after stimulation with doxycycline. Lysis, 
gel and blotting were performed as described previously27. For the detection, the 
primary antibodies for filamin A (Thermo Fisher, MA5-11705) and tubulin (Sigma, T 
9026) were used and diluted by manufacturer’s instructions. For secondary antibody 
detection, ALEXA FLUOR PLUS 800 (Thermo Fisher, A32730) were used, imaged 
with the Odyssey Fa and analyzed and quantified by Image Studio Software (LiCor). 
 
The transcription factor binding sites were published previously136 
 
RNA extraction was performed via the Total RNA Kit, peqGOLD (VWR) as by 
manufacturer’s instructions. The cDNA synthesis was performed using the qScript 
cDNA synthesis kit (Quanta Bioscience) as by manufacturer’s protocol. 
Analysis of expression was performed with the Lightcycler 480 (Roche) and the 
Universal Probe Library (Roche) with following probe and primer (forward/reverse) 
combinations, all results were normalized to GAPDH as housekeeper: 
FLNA, Probe 32, TCGCTCTCAGGAACAGCA / TTAATTAAAGTCGCAGGCACCTA 
JUN, Probe 19, CCAAAGGATAGTGCGATGTTT / CTGTCCCTCTCCACTGCAAC 
GAPDH, Probe 45, TCCACTGGCGTCTTCACC / GGCAGAGATGATGACCCTTTT 
KLF4, Probe 83, TGACTTTGGGGTTCAGGTG / GTGGAGAAAGATGGGAGCAG 
EGR1, Probe 22, AGCCCTACGAGCACCTGAC / GGTTTGGCTGGGGTAACTG 
FOSL2, Probe 70, ACGCCGAGTCCTACTCCA / TGAGCCAGGCATATCTACC 
 
Confocal images and 3D stacks were acquired using a Leica TCS SP8 SMD 
microscope equipped with a 40x HC PL APO oil objective. Pinhole size was adjusted 
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to 1.0 airy units and sequential scanning was performed at 400 Hz. 405nm, 488nm and 
561nm laser lines were used for excitation. 
 
For immunofluorescence staining, cells were fixed for 10 min with 4% EM grade 
formaldehyde. After 5 min washing with PBS, samples were permeabilized for 10 min 
with 0.5% TX-100 in PBS. Unspecific binding was blocked by 30 min incubation with 
5% BSA (Sigma) at RT. Cells were then incubated overnight (4 °C) with the primary 
antibody for filamin A diluted according to the manufacturer’s instructions (1:400, 
Thermo Fisher, MA5-11705). After 3 x 10 min washing with PBS, samples were 
incubated with secondary antibodies (1:500, AF488 goat-anti-mouse AB_2534069), 
rhodamine phalloidin (1:300, Sigma-Aldrich) and DAPI (0.5 µg/ml, Sigma-Aldrich) for 
1 hour at RT, washed again 3 x 10 min with PBS. All stainings were performed in 
ibiTreat 8 well µ-slides (ibidi GmbH) coated with fibronectin (Corning). Total 
fluorescence intensities and nuclear shape factors were quantified using ImageJ v1.52. 
Z-plane scaled 3D stacks were rendered using the Leica LAS X software platform.  
 
For the knockdown of JUN, a siRNA was used and compared to a negative control 
(Silencer Select, Thermo Fisher, assay s7659 and control 4390843). Cells were 
transfected with the K2 transfection reagent (Biontex) according to the manufacturer’s 
recommendations. 
 
For analysis of SRF/MRTF signaling, the pgl4.34 Plasmid (Promega, 9PIE135) was 
used. Transfection was performed in 6-well with cells grown to 80% confluence with 
K2 transfection reagent (Biontex, Germany) according to the manufacturer’s 
instructions, into cells stimulated with 5µg/ml doxycycline for 24h. Luciferase 
measurement was performed 24h after transfection, as described previously28. 
 
Detailed description of production of the stamps and measurements are published in 
Schreiber et al. 140 and further described in the supplemental methods.  
The motility parameters are defined as: 
𝒗𝐫𝐮𝐧: The run velocity is defined as the mean over the tangential velocity for time points  
when cells are in the run state 𝑣𝑟𝑢𝑛 = 〈|𝑣𝑡𝑎𝑛𝑔|〉.  
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𝝉𝐫𝐮𝐧 , 𝝉𝐫𝐞𝐬𝐭: To evaluate the persistence times of run and rest states 𝜏run and 𝜏rest, the 
survival function 𝑆(𝑡) = P(𝑇 > 𝑡) is calculated. 𝜏run and 𝜏rest are determined by fitting 
log(𝑆(𝑡)) by the function 𝑓(𝑡) = −
1
𝜏
 𝑡 + 𝑐 evaluated at 𝑡 ∈  [2; 16 ]ℎ. Very small times 
are excluded because defiations from an exponential behavior are observed here. To 
reduce the effects of the limited time window, only states that start at least 16 h before 
the end of the corresponding cell track are evaluated, while the fitting range for 𝑆(𝑡) 
ends at 16 h. The error range given is the 99% confidence interval for the fit. 
 𝑷𝐫𝐮𝐧: The fraction of time cells spend in the run state is defined as the time cells are 
in the run state divided by the total time of the trajectories. 
q: The persistence parameter q is defined as the maximum distance between two 
points of a cell trajectory divided by the total path length of the trajectory. This is 
averaged over all cells 𝑞 = 〈
max(𝜑)−min(𝜑)
∑ |𝜑𝑖|𝑖
〉  
 
Results are expressed as the mean ± SD of at least three biological replicas and 
analyzed using a two-sided student’s t-test, if not stated otherwise. Software GraphPad 
Prism v6 and SigmaPlot 11 were utilized for the analysis of the data. 
 
The data that support the findings of this study are available from the corresponding 
author upon reasonable request.  
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4.6. Supplements 
4.6.1. Supplemental methods 
Micropatterning / 1D Migration 
Production of stamps: 
To a master for stamp preparation, silicon wafers were coated with TI Prime adhesion 
promoter and AZ40XT (MicroChemicals) photo-resist. Desired areas were exposed to 
UV light using laser direct imaging (Protolaser LDI, LPKF). The photoresist was then 
developed (AZ 826 MIF, MicroChemicals) and silanized (Trichloro(1H,1H,2H,2H-
perfluoro-octyl)silane, Sigma-Aldrich). To create the stamp, polydimethylsiloxane 
(PDMS) monomer and crosslinker (DC 184 elastomer kit, Dow Corning) were mixed in 
a 10:1 ratio, poured onto the stamp master, degassed in a desiccator, and cured 
overnight at 50°C. 
Microcontact printing: 
Microcontact printing was used to produce fibronectin-coated ring-shaped lanes. 
PDMS stamps were treated with UV light (PSD-UV, novascan) for 5 min. Then the 
stamps were incubated for 45 min in a solution containing 40 µg/ml ﬁbronectin (Yo 
proteins) and 10 µg/ml ﬁbronectin labeled with Alexa Fluor 647 (Alexa Fluor NHS Ester, 
Thermo Fisher Scientific) dissolved in ultrapure water. Next, stamps were washed with 
ultrapure water, dried and placed on a petri dish (µ-Dish, Ibidi) which had been 
activated with UV light for 15 min. A droplet of a 2 mg/ml poly-L-lysine-grafted 
polyethylene glycol (PLL-PEG) (2 kDa PEG chains, SuSoS) solution (dissolved in a 
solution of 10 mM HEPES and 150 mM NaCl was placed at the edge of the stamps 
and drawn into the spaces between surface and stamp by capillary action. Stamps 
were removed and a glass coverslip was placed on the dish surface to ensure complete 
coverage of the surface with PEG solution. After a 30-min incubation, the coverslip was 
removed, and the surface was washed three times with phosphate-buffered saline 
(PBS) and stored in PBS until cells were seeded. 
Cell Culture 
MDA-MB-231 breast cancer cells were cultured in L15 medium (sigma aldrich) 
containing 10% TET system approved fetal calf serum (FCS) (Clontech). Cells were 
incubated at 37°C in a humidified atmosphere. For cell motility measurements, cells 
were cultured in medium containing 0 or 5 µg/ml Doxycycline for 44h. Then, about 
10,000 cells were seeded per dish (µ-Dish, Ibidi). After 3 h, cell medium was replaced 
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with fresh medium containing 25 nM Hoechst 33342 dye (Invitrogen) and 
measurements were started within 1 hour.  
Time-Lapse Microscopy 
Scanning time-lapse measurements were performed using an automated inverted 
microscope (Nikon Ti) equipped with a 10x objective, a LED lamp (Spectra X, 
lumencor) and a sCMOS camera (pco.edge 4.2, pco). Cells were maintained at 37°C 
and a humidified atmosphere using a heating chamber (okolab). Phase-contrast and 
fluorescent images were automatically acquired every 10 min. 
Cell Tracking 
Cell tracking was performed using the image-processing software ImageJ. Isolated 
cells confined in the ring-shaped lanes were identified by eye. Fluorescence images of 
the nuclei were preprocessed by applying a bandpass filter and a threshold for 
fluorescence intensity, and the centers of mass of the stained nuclei were identified. 
Cell tracking was stopped in the case of cell division or when cells spanned over the 
middle part of the ring pattern. Cell tracks shorter than 20 h, as well as tracks of dying 
or non-moving cells were excluded from further analysis.  
Data Analysis 
Two-state analysis of tracks: 
Track analysis was performed in MATLAB (Mathworks). A circle was fitted to cell 
position data to find the center of the ring-shaped lane. Switching to polar coordinates, 
the tangential component of the cell velocity was evaluated as), where indicates the 
azimuthal cell position at time i and R indicates the mean radius of the micropattern (R 
= 65 µm). To distinguish run from rest states, a iterative change-point analysis in 
combination with a classification of cell dynamics in the time intervals between change-
points was applied. Change-points were identified when they exceeded a confidence 
level for the existence of change-points that was calculated via bootstrap analysis of 
the cumulative sum of the angular velocity. For all intervals between change points this 
was repeated until no more change-points were found. The resulting intervals were 
classified into run and rest states by analyzing the mean square displacement. Details 
are published in Schreiber et al.[cite] 
The run velocity is defined as the mean over the tangential velocity for time points 
when cells are in the run state .  
To evaluate the persistence times of run and rest states and the survival function  is 
calculated. and are determined by fitting  by the function  evaluated at . Very small 
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times are excluded because deviations from an exponential behavior are observed 
here. To reduce the effects of the limited time window, only states that start at least 16 
h before the end of the corresponding cell track are evaluated, while the fitting range 
for ends at 16 h. The error range given is the 99% confidence interval for the fit. 
The fraction of time cells spend in the run state is defined as the time cells are in the 
run state divided by the total time of the trajectories. 
q: The persistence parameter q is defined as the maximum distance between two 
points of a cell trajectory divided by the total path length of the trajectory. This is 
averaged over all cells   
 
4.6.2. Supplemental figures 
 
Supplement S 9  
Analysis of different potential transcription factors for FLNA was performed after miR-200c induction. 
The graphs show the RT-qPCR results at different time points, with no consistent effect for any factor 
but JUN 
 
4.6.3. Supplemental movies 
The supplemental movies be viewed at in the online version of the publication or on 
https://www.cup.lmu.de/pb/aks/ewagner/projects/  
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5. Summary  
In this work, novel functions of the two prominent miRNAs, miR-200c and miR-27a 
were unraveled. 
In the first part, our findings in chapter 2 revealed a novel role of the oncomir miR-27a 
in breast cancer. In the current literature, a high expression of miR-27a indicated more 
aggressive and metastatic tumors157. This is inline with the retrospective analysis 
shown in chapter 2.3.4. Still, in our analysis, by taking clinical settings into account, as 
well as molecular properties of the tumor cells (e.g. the receptor status), we uncovered 
a novel and ambivalent role of miR-27a as prognostic tumor marker.  
The high expression of this oncomiR showed to be beneficial for a certain, miR-27a 
high expressing subgroup of estrogen receptor positive patients – but only if they 
underwent endocrine treatments. Or, conversely stated, patients with estrogen 
receptor positive phenotypes but low tumoral miR-27a levels, may not receive an 
optimal treatment with regular endocrine therapies. Although a therapeutic use of 
miR-27a would most likely not meet a favorable risk-benefit profile, the analysis of the 
miR-27a expression status could support the treating physician in the selection of a 
better and thus personalized therapies.  
The second part of this work is focusing on miR-200c in breast cancer, which is one of 
the most important tumor suppressing miRNAs. Most previous studies were based on 
the artificial overexpression of the miRNA or on in vivo correlations. Therefore, it is 
possible that the unnatural surplus of this miRNA, acting as inhibitor, could lead to 
observations that are not relevant in the regular biological setting, as also discussed in 
chapter 3.4. Thus, a removal of miR-200c of an otherwise unmodified cellular breast 
cancer cell system, was chosen to illuminate another perspective, revealing novel roles 
and validating previous findings. For this reason, genomic knock-outs of miR-200c 
were conducted in the miR-200c high expressing MCF7 breast cancer cell line and 
were followed by a comprehensive proteomic screen, as described in chapter 3. With 
this means, a group of novel putative miR-200c targets were found. Interestingly, a 
major proportion of these potential target proteins did not contain any miR-200c binding 
sites, indicating that the effects were based on indirect mechanisms, like subtle 
changes in pathways upstream of the found proteins. 
Consequently, the role of miR-200c in the regulation of one of these targets, the 
important cytoskeletal protein filamin A, was investigated in chapter 4. MiR-200c is 
known to inhibit progression of EMT by targeting ZEB1/2, resulting in an increase of 
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E-cadherin expression and therefore impede the transition. By our choice of 
appropriate cell models for these experiments, this particular mode of influence was 
excluded due to genetic predisposition of the cell lines, each respectively not 
expressing one of those key proteins. Thus, additionally to the “loss of function” 
knock-out model, an inducible overexpression of miR-200c was generated in an 
elsewise miR-200c-null cell line. Experiments conducted with these cell line models 
showed a strong effect of miR-200c induction on the migration of the cell lines, as well 
as a distinctive cellular remodeling after long-term induction of the miRNA. Filamin A 
was regarded as a potential key protein in those processes and a regulatory pathway 
of miR-200c on filamin A was indicated, based on targeting the transcriptional 
regulators JUN and SRF. 
These novel regulatory networks that are indicated, may indicate the potential impact 
of miR-200c in a broad variety of breast cancer cells. All in all, contrary to miR-27a, 
miR-200c could have the potential to act as tumor suppressing agent. 
Our studies altogether showed the potential of miRNAs as therapeutics and 
biomarkers, enabling physicians to better determine the characteristics of the tumor.  
MiRNA signatures of breast cancer patients could be routinely measured in clinical 
practice, and miR-27a could be one important indicator in helping to choose the most 
promising therapeutic regimes.  
For tumor suppressing miRNAs like miR-200c, one promising route of miRNA 
(or siRNA) delivery may lay in mimicking this intrinsic trafficking, by packaging miRNAs 
in artificial exosomes, in poly- or lipoplex formulations 158 or in future applications 
“reprogramming” of patient-derived exosomes159,160. 
Therefore, even more than 25 years after the discovery 1, miRNA research remains a 
field of high interest and ever rising clinical relevance. Due to standardized, fast and 
cheap genomic screening technologies, the utilization of clinical miRNA screenings for 
tumor classification and thus improved and personalized treatments are as close as 
never before, and miR-27a and miR-200c may hold an important role in the future. 
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6. Appendix 
6.1. Abbreviations 
AGO Argonaute 
ATCC American Type Culture Collection 
CDNA Complementary DNA 
CT Cycle of threshold 
DAPI 4',6-diamidino-2-phenylindole 
DAVID Database for Annotation, Visualization and Integrated Discovery 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DOX Doxycycline 
DXR Doxorubicin 
EDTA Ethylenediamine tetraacetic acid 
ELISA Enzyme linked immunosorbent assay 
EMT Epithelial-mesenchymal transition 
ENDO Endoxifen 
ER +/- Estrogen receptor positive / negative 
FCS Fetal calf serum 
FDR False discovery rate 
FUL Fulvestrant 
HSA Homo sapiens 
HR +/- Hormone receptor positive / negative 
IF Immunofluorescence 
IHC   Immunohistochemistry 
KEGG Kyoto Encyclopedia of Genes and Genomes 
KO Knock-out 
LNA Locked nucleic acid 
LSM Laser scanning microscopy 
MET Mesenchymal-epithelial transition 
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MIRNA MicroRNA 
MMU Mus musculus 
MRNA MessengerRNA 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NET Buffer containing NaCl, EDTA and Tris-HCl 
PBS Phosphate buffered saline 
POLYA Polyadenylation 
RISC RNA-induced silencing complex 
RLUC Renilla luciferase reporter plasmid 
RNA Ribonucleic acid 
RNAI RNA interference 
RT-PCR Reverse transcription - polymerase chain reaction 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate - polyacrylamide gel 
SEM Standard error of the mean 
SIRNA Small interfering RNA 
SLP Stem loop primer 
TAM Tamoxifen 
TOR Toremifen 
TRISHCL Tris(hydroxymethyl)aminomethane hydrochloride 
UTR Untranslated region 
W:W Weight to weight ratio 
WB Western blot 
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6.2. Genes and proteins 
AGR2 
Anterior gradient protein 2 homolog 
AKT Protein kinase B (PKB) 
ALDH7A1 Alpha-aminoadipic semialdehyde dehydrogenase 
BCL2 B-cell lymphoma 2 
BMI1 Polycomb ring finger oncogene 
CA2 Carbonic anhydrase 2 
CDK4/6 Cyclin-dependent kinase 4/6 
CTTN;EMS1 Src substrate cortactin 
DGCR8 Di George syndrome critical region 8 (= Pasha in D. melanogaster) 
E2F1 Transcription factor E2F1 
EGFP Enhanced green fluorescent protein 
EGFR Epidermal growth factor receptor 
ERBB Epidermal growth factor receptor family 
ESR1 Estrogen receptor alpha 
FN1 Fibronectin 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GOT2 Aspartate aminotransferase 
GSTM3 Glutathione S-transferase Mu 3 
HER2 Human epidermal growth factor receptor 2 
HSP90AA1 Heat shock protein HSP 90-alpha 
JUN Jun proto-oncogene 
KRAS Kirsten rat sarcoma viral oncogene homolog 
KYNU Kynureninase 
LIN-14 Protein lin-14 (C. elegans) 
LIN-4 MicroRNA lin-4 (C. elegans) 
MAPK Mitogen-activated protein kinases 
MCM4 DNA replication licensing factor MCM4 
MEKK1 Mitogen-activated protein kinase kinase kinase 1 
MSN Moesin 
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MYC V-myc avian myelocytomatosis viral oncogene homolog 
NFΚB Protein complex, nuclear factor kappa-light-chain-enhancer  
of activated B cells P53 Tumor protein p53 
PHGDH D-3-phosphoglycerate dehydrogenase 
PI3K Phosphatidylinositide 3-kinases 
PKC Protein kinase C 
POL II RNA polymerase II 
PPM1F Protein phosphatase 1F 
PTEN Phosphatase and tensin homolog 
RAB14 Ras-related protein Rab-14 
SH3BGRL SH3 domain-binding glutamic acid-rich-like protein 
SLC3A2 4F2 cell-surface antigen heavy chain 
SRF Serum response factor (c-fos serum response element-binding 
transcription factor) TNFΑ Tumor necrosis factor alpha 
TPI1 Triosephosphate isomerase 
TRBP Transactivation response element RNA-binding protein 
TPM1 Tropomyosin alpha-1 chain 
TRKB Neurotrophic tyrosine kinase, receptor, type 2 (NTRK2) 
TUBB3 Tubulin, beta 3 class III 
UGDH UDP-glucose 6-dehydrogenase 
WARS Tryptophan-tRNA ligase 
WNT Wingless-type MMTV integration site family 
ZEB1/2 Zinc finger E-box binding homeobox 1/2 (TCF8/SIP1) 
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